Scorpius (SCPX) 10-K/A 24 Apr 19 2018 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 28, 2019	Jun. 30, 2018
Document and Entity Information [Abstract]
Document Type	10-K/A
Amendment Flag	true
Amendment Description	This Amendment No. 1 is being filed for the sole purpose of correcting an error regarding the number of the Company’s shares of common stock, par value $0.0002 per share (the “Common Stock”), that were outstanding as of March 28, 2019. The Original Form 10-K disclosed that as of March 28, 2019, the Company had 33,091,824 shares of Common Stock outstanding; however, the correct number of shares of the Company’s Common Stock outstanding as of March 28, 2019 was 34,093,067.
Document Period End Date	Dec. 31, 2018
Entity Registrant Name	HEAT BIOLOGICS, INC.
Entity Central Index Key	0001476963
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Trading Symbol	HTBX
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 49,651,206
Entity Common Stock, Shares Outstanding		34,093,067

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current Assets
Cash and cash equivalents	$ 22,154,251	$ 9,763,067
Short-term investments	5,570,027
Accounts receivable	28,538	14,833
Prepaid expenses and other current assets	961,317	1,967,257
Total Current Assets	28,714,133	11,745,157
Property and Equipment, net	643,146	286,891
Other Assets
Restricted cash		2,292
In-process R&D	5,866,000	5,866,000
Goodwill	2,189,338	2,189,338
Deposits	351,220	69,798
Deferred financing costs		30,000
Total Other Assets	8,406,558	8,157,428
Total Assets	37,763,837	20,189,476
Current Liabilities
Accounts payable	974,619	1,033,680
Deferred revenue, current portion	1,032,539	7,026,388
Contingent consideration, current portion	1,187,000
Accrued expenses and other liabilities	1,678,051	2,276,431
Total Current Liabilities	4,872,209	10,336,499
Long Term Liabilities
Other long-term liabilities	213,724	160,559
Deferred tax liability	316,733	1,302,220
Deferred revenue, net of current portion	200,000
Contingent consideration, net of current portion	1,918,225	2,609,289
Total Liabilities	7,520,891	14,408,567
Commitments and Contingencies
Stockholders' Equity
Common stock, $.0002 par value; 100,000,000 shares authorized, 32,492,144 and 4,200,310 issued and outstanding at December 31, 2018 and 2017, respectively	6,499	840
Additional paid-in capital	114,883,135	76,382,262
Accumulated deficit	(84,580,180)	(68,846,326)
Accumulated other comprehensive loss	(19,904)	(166,025)
Total Stockholders' Equity - Heat Biologics, Inc	30,289,550	7,370,751
Non-Controlling Interest	(46,604)	(1,589,842)
Total Stockholders' Equity	30,242,946	5,780,909
Total Liabilities and Stockholders' Equity	$ 37,763,837	$ 20,189,476

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Common stock, par value per share	$ 0.0002	$ 0.0002
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	32,492,144	4,200,310
Common stock, shares outstanding	32,492,144	4,200,310

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue:
Grant and licensing revenue	$ 5,793,849	$ 1,519,943
Operating expenses:
Research and development	16,233,014	8,267,549
General and administrative	7,025,212	6,370,954
Change in fair value of contingent consideration	495,936	224,289
Total operating expenses	23,754,162	14,862,792
Loss from operations	(17,960,313)	(13,342,849)
Interest income	265,752	22,167
Other income, net	117,780	101,276
Total non-operating income, net	383,532	123,443
Net loss before income tax benefit	(17,576,781)	(13,219,406)
Income tax benefit	985,488	809,540
Net loss	(16,591,293)	(12,409,866)
Net loss - non-controlling interest	(857,439)	(568,195)
Net loss attributable to Heat Biologics, Inc.	$ (15,733,854)	$ (11,841,671)
Net loss per share attributable to Heat Biologics, Inc.- basic and diluted	$ (0.9)	$ (3.08)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted	17,485,461	3,845,342
Other comprehensive loss:
Net loss	$ (16,591,293)	$ (12,409,866)
Unrealized gain (loss) on foreign currency translation	146,121	(93,794)
Total comprehensive loss	(16,445,172)	(12,503,660)
Comprehensive loss - non-controlling interest	(857,439)	(568,195)
Comprehensive loss attributable to Heat Biologics, Inc.	$ (15,587,733)	$ (11,935,465)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	APIC [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Gain (Loss) [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2016	$ 524	$ 65,872,943	$ (57,004,655)	$ (72,231)	$ (1,956,647)	$ 6,839,934
Public offering, 575,000 shares, net of underwriters discounts	115	4,182,885				4,183,000
Public offering, 620,650 shares, net of underwriters discounts	124	2,446,855				2,446,979
Issuance of common stock, 234,858 shares	47	2,463,133				2,463,180
Issuance of common stock for acquisition of Pelican, 133,106 shares	27	1,051,973				1,052,000
Acquisition of non-controlling interest of Pelican					935,000	935,000
Stock issuance costs		(324,654)				(324,654)
Stock-based compensation	3	689,127				689,130
Other comprehensive income (loss)				(93,794)		(93,794)
Net loss			(11,841,671)		(568,195)	(12,409,866)
Balance at Dec. 31, 2017	840	76,382,262	(68,846,326)	(166,025)	(1,589,842)	5,780,909
Public offering, 14,375,000 shares, net of underwriters discounts	2,875	20,697,122				20,699,997
Public offering, 9,200,000 shares, net of underwriters discounts	1,840	13,798,160				13,800,000
Exercise of warrants, 3,054,667 shares	611	4,837,982				4,838,593
Issuance of common stock, 1,566,997	314	3,909,779				3,910,093
Acquisition of non-controlling interest of Heat I/Pelican	7	(2,400,684)			2,400,677
Stock issuance costs		(3,130,133)				(3,130,133)
Stock-based compensation	12	788,647				788,659
Other comprehensive income (loss)				146,121		146,121
Net loss			(15,733,854)		(857,439)	(16,591,293)
Balance at Dec. 31, 2018	$ 6,499	$ 114,883,135	$ (84,580,180)	$ (19,904)	$ (46,604)	$ 30,242,946

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Statement of Stockholders' Equity [Abstract]
Public offering, shares	14,375,000	575,000
Public offering, shares	9,200,000	620,650
Exercise of warrants, shares	3,054,667
Issuance of common stock, shares	1,566,997	234,858
Issuance of common stock Pelican, shares		133,106

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash Flows from Operating Activities
Net loss	$ (16,591,293)	$ (12,409,866)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	237,318	134,084
Stock based compensation	788,659	689,130
Change in fair value of contingent consideration	495,936	224,289
Unrealized loss on investments	131
Increase (decrease) in cash arising from changes in assets and liabilities:
Accounts receivable	(14,094)	67,767
Prepaid expenses and other current assets	1,000,961	(1,624,185)
Deposits	(281,422)
Deferred financing costs	30,000	(30,000)
Accounts payable	(55,820)	(175,901)
Deferred revenue	(5,793,849)	7,026,388
Deferred tax liability	(985,487)	(809,540)
Accrued expenses and other liabilities	(595,896)	806,158
Other long-term liabilities	53,165	(300,875)
Net Cash Used in Operating Activities	(21,711,691)	(6,402,551)
Cash Flows from Investing Activities
Purchase of Pelican, net		(468,801)
Purchase of short-term investments	(5,570,158)
Purchase of property and equipment	(593,573)	(61,383)
Net Cash Used in Investing Activities	(6,163,731)	(530,184)
Cash Flows from Financing Activities
Proceeds from public offerings, net of underwriting discounts	34,499,997	6,629,979
Proceeds from the issuance of common stock, net of commissions	3,910,093	2,463,180
Proceeds from the exercise of warrants	4,838,593
Stock issuance costs	(3,130,133)	(324,654)
Net Cash Provided by Financing Activities	40,118,550	8,768,505
Effect of exchange rate changes on cash and cash equivalents	145,764	(14,249)
Net Increase in Cash and Cash Equivalents and Restricted Cash	12,388,892	1,821,521
Cash and Cash Equivalents and Restricted Cash - Beginning of Period	9,765,359	7,943,838
Cash and Cash Equivalents and Restricted Cash - End of Period	22,154,251	9,765,359
Supplemental Disclosure for Cash Flow Information
Contingent consideration		2,385,000
Issuance of common stock for purchase of Pelican		1,052,000
Acquisition of non-controlling interest of Heat I/Pelican	$ 2,400,677

Organization

Organization	12 Months Ended
	Dec. 31, 2018
Organization
Organization	1. Organization Heat Biologics, Inc. (“Heat” or “the Company”) is a biopharmaceutical company developing immunotherapies with the goal of activating a patient’s immune system against cancer through T-cell activation. Our T-cell Activation Platform (TCAP), includes two variations for intradermal administration, Immune Pan-antigen Cytotoxic Therapy ( ImPACT ® ComPACT ™ We continue to enroll patients in our Phase 2 clinical trial for advanced non-small cell lung cancer (NSCLC), in combination with either Bristol-Myers Squibb’s nivolumab (Opdivo ® ® Our T-cell Activation Platform (TCAP), includes two variations, ImPACT ® ComPACT ™ We believe the advantage of our approach is that our biologic agents deliver a broad range of tumor antigens that are unrecognized by the patient’s immune system prior to the malignant rise of the patient’s tumor. TCAP combines these tumor associated antigens with a powerful, naturally occurring immune adjuvant, gp96, to actively chaperone these antigens out of our non-replicating allogenic cell-based therapy into the local microenvironment of the skin. The treatment primes immune recognition to activate T-cells to seek and destroy the cancer cells throughout the body. These TCAP agents can be administered with a variety of immuno-modulators to enhance a patient’s immune response through ligand specific T-cell activation. Unlike many other “patient specific” or autologous immunotherapy approaches, our drugs are fully-allogenic, “off-the-shelf,” products which means that we can administer immediately without the extraction of blood or tumor tissue from each patient or the creation of an individualized treatment based on these patient materials. Our TCAP product candidates from our ImPACT ® ComPACT ™ In October 2018, Heat entered into an agreement with the University of Miami (“UM”) whereby UM exchanged its shares of stock in Heat’s subsidiaries, Heat I, Inc. and Pelican Therapeutics, Inc. (“Pelican”), a related party prior to acquisition. The stock exchange Pelican In November 2018 Heat formed two wholly-owned subsidiaries, Delphi Therapeutics, Inc. and Scorpion Biosciences, Inc. Operations of Pelican are included in the consolidated statement of operations and comprehensive loss from the acquisition date. Heat’s product candidates require clinical trials and approvals from regulatory agencies, as well as acceptance in the marketplace. Part of Heat’s strategy is to develop and commercialize some of its product candidates by continuing existing arrangements with academic and corporate collaborators and licensees and by entering into new collaborations. All share numbers in the consolidated financial statements and footnotes below have been adjusted for the one-for-ten reverse stock split effective January 19, 2018.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. (“Heat I”) Heat Biologics III, Inc. (“Heat III”), Heat Biologics IV, Inc. (“Heat IV”), Heat Biologics GmbH, Heat Biologics Australia Pty Ltd, and Zolovax, Inc. Additionally, beginning April 28, 2017 the accompanying consolidated financials include Pelican. As of December 31, 2018 there was no activity for Delphi Therapeutics, Inc. or Scorpion Biosciences, Inc. The functional currency of the entities located outside the United States of America (the foreign entities) is the applicable local currency of the foreign entities. Assets and liabilities of the foreign entities are translated at period-end exchange rates. Statement of operations accounts are translated at the average exchange rate during the period. The effects of foreign currency translation adjustments are included in other comprehensive loss, which is a component of accumulated other comprehensive loss in stockholders’ equity. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2018 and 2017, Heat held 100% and 92.5% controlling interest respectively in Heat I. The December 31, 2018 year-end financials include 85% controlling interest in Pelican and the December 31, 2017 year-end financials include 80% controlling interest in Pelican as of April 28, 2017. Heat accounts for its less than 100% interest in the consolidated financial statements in accordance with U.S. GAAP. Accordingly, the Company presents non-controlling interest as a component of stockholders’ equity on its consolidated balance sheets and reports non-controlling interest net loss under the heading “net loss – non-controlling interest” in the consolidated statements of operations and comprehensive loss. Liquidity and Capital Resources The Company has an accumulated deficit of approximately $84.6 million as of December 31, 2018 and a net loss of approximately $16.6 million for the twelve months ended December 31, 2018 and has not generated significant revenue or positive cash flows from operations. The Company expects to incur significant expenses and continued losses from operations for the foreseeable future. The Company expects its expenses to increase in connection with its ongoing activities, particularly as the Company continues its research and development and advances its clinical trials of, and seek marketing approval for, its product candidates and as the Company continues to fund the Pelican matching funds required in order to access the CPRIT Grant. In addition, if the Company obtains marketing approval for any of its product candidates, the Company expects to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, the Company will need to obtain substantial additional funding in connection with its continuing operations. Adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or any future commercialization efforts. To meet its capital needs, the Company intends to continue to consider multiple alternatives, including, but not limited to, additional equity financings such as sales of its common stock under at-the-market offerings, if available, debt financings, partnerships, collaborations and other funding transactions. This is based on the Company’s current estimates, and the Company could use its available capital resources sooner than it currently expects. The Company is continually evaluating various cost-saving measures in light of its cash requirements in order to focus resources on its product candidates. The Company will need to generate significant revenues to achieve profitability, and it may never do so. As of December 31, 2018, the Company had approximately $27.7 million in cash, cash equivalents and short term investments and believes it has the ability to fund its operations within one year from the date these financial statements are issued. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, useful lives of fixed assets, contingent consideration, income taxes and stock-based compensation. Actual results may differ from those estimates. Segments The Company has one reportable segment – the development of immunotherapies designed to activate and expand a patient’s T-cell mediated immune system against cancer. Cash and Cash Equivalents and Restricted Cash The Company considers all cash and other highly liquid investments with initial maturities from the date of purchase of three months or less to be cash and cash equivalents. The Company had a restricted cash balance of $0 and $2,292 at December 31, 2018 and 2017, respectively. Concentration of Credit Risk At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurable limits. The Company has never experienced any losses related to these balances. As of December 31, 2018 and 2017, cash amounts in excess of $250,000 were not fully insured. The uninsured cash balance as of December 31, 2018 was $21,904,251. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents. Property and Equipment Property and equipment are stated at cost and are capitalized. Depreciation is calculated using the straight-line method and is based on estimated useful lives of five years for lab equipment and computer equipment, and seven years for furniture and fixtures. Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during each year. Fully diluted net loss per share is computed using the weighted average number of common shares and dilutive securities outstanding during each year. Dilutive securities having an anti-dilutive effect on diluted loss per share are excluded from the calculation. Fair Value of Financial Instruments The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other payables approximate fair value due to their short maturities. As a basis for determining the fair value of certain of the Company’s financial instruments, the Company utilizes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level I – Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level II – Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level III – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The Company's cash equivalents are classified within Level I of the fair value hierarchy. As of December 31, 2018 and 2017, the fair values of cash, accounts payable, and accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. The Company’s short-term investments consist of Level I securities which are comprised of highly liquid money market funds. The estimated fair value of the short-term investments was based on quoted market prices. There were no transfers between fair value hierarchy levels during the years ended December 31, 2018 or 2017. The fair value of financial instruments measured on a recurring basis is as follows: As of December 31, 2018 Description Total Level 1 Level 2 Level 3 Assets: Short-term investments $ 5,570,027 $ 5,750,027 — — Liabilities: Contingent consideration 3,105,225 — — $ 3,105,225 As of December 31, 2017 Description Total Level 1 Level 2 Level 3 Liabilities: Contingent consideration $ 2,609,289 — — $ 2,609,289 The following table summarizes the change in fair value, as determined by Level 3 inputs, for all assets and liabilities using unobservable Level 3 inputs for the year ended December 31, 2018: Contingent Consideration Balance at December 31, 2016 $ — Acquisition of Pelican 2,385,000 Change in fair value 224,289 Balance at December 31, 2017 2,609,289 Change in fair value 495,936 Balance at December 31, 2018 $ 3,105,225 The change in the fair value of the contingent consideration of $495,936 and $224,289 for the years ended December 31, 2018 and 2017 was primarily due to the effect of the change in discount rate, probability of achieving milestones, and passage of time on the fair value measurement. Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statement of operations and comprehensive loss. The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements of contingent consideration classified as Level 3 as of December 31, 2018: Valuation Significant Weighted Average Contingent Consideration Probability weighted Milestone dates 2019-2025 Discount rate 13.82% to 3.66% Probability of occurrence 23% to 86% Income Tax Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In accordance with FASB ASC 740, Accounting for Income Taxes On December 22, 2017, the Tax Cuts and Jobs Act (“Tax Act”) was signed into law. The Tax Act lowered the Federal corporate tax rate from 34% to 21% and made numerous other tax law changes. The Company has measured deferred tax assets at the enacted tax rate expected to apply when these temporary differences are expected to be realized or settled. Under the guidance of SAB 118, the Company is required to recognize the effect of tax law changes in the period of enactment. Reasonable estimates were made based on the Company’s analysis of the Tax Act. These provisional amounts were adjusted during 2018 when additional information was obtained with no material adjustments. Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method that requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The fair value of restricted stock units is estimated based on the closing price of the Company's stock on the date of grant, and for the purposes of expense recognition, the total new number of shares expected to vest is adjusted for estimated forfeitures. Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes-Merton option pricing model on the date of grant for stock options and are recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term for the years ended December 31, 2018 and 2017 represents the average time that options are expected to be outstanding based on the average of the vesting term and the contractual term of the option. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense in the period over which services are received. Net loss attributable to non-controlling interests Net loss attributable to non-controlling interests is the result of the Company's consolidation of subsidiaries of which it does not own 100%. In October 2018, the Company entered into an agreement with the University of Miami (“UM”) whereby UM exchanged its shares of stock in the Company’s subsidiaries, Heat I, Inc. and Pelican, a related party prior to acquisition, for 35,000 shares of the Company’s common stock. The stock exchange Pelican Revenue Recognition Effective January 1, 2018, the Company has adopted on a modified retrospective basis Accounting Standards Codification (ASC) Topic 606. The Company’s sole source of revenue is grant revenue related to the CPRIT contract, which is being accounted for under ASC 606. ASC 606 introduces a new framework for analyzing potential revenue transactions by identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when (or as) the Company satisfies a performance obligation. The performance obligations of the Contract include developing a human TNFRSF25 agonist antibody for use in cancer patients through research and development efforts and a noncommercial license from CPRIT-funded research to CPRIT and other government agencies and institutions of higher education in Texas. Management has concluded that the license and R&D services should be combined into a single performance obligation as both are highly interdependent - a license cannot be effectively granted without the corresponding research basis and CPRIT cannot benefit from the license without the R&D services and are therefore not capable of being distinct. The CPRIT grant covers a three-year period from June 1, 2017 through May 31, 2019, for a total grant award of up to $15.2 million. CPRIT advances grant funds upon request by the Company consistent with the agreed upon amounts and schedules as provided in the contract. The first tranche of funding of $1.8 million was received in May 2017, and a second tranche of funding of $6.5 million was received in October 2017. The next tranche of funding is expected to be requested and received in early 2019. Funds received are reflected in deferred revenue as a liability until revenue is earned. Grant revenue is recognized when qualifying costs are incurred. As of December 31, 2018, the deferred revenue balance was $1.0 million with $7.3 million recognized as revenue since contract inception. Business Combinations We account for acquisitions using the acquisition method of accounting, which requires that all identifiable assets acquired and liabilities assumed be recorded at their estimated fair values. The excess of the fair value of purchase consideration over the fair values of identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions. Critical estimates in valuing certain intangible assets include but are not limited to future expected cash flows from acquired patented technology. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Other estimates associated with the accounting for acquisitions may change as additional information becomes available regarding the assets acquired and liabilities assumed (see Note 4). Goodwill and In-Process Research and Development We classify intangible assets into three categories: (1) intangible assets with definite lives subject to amortization, (2) intangible assets with indefinite lives not subject to amortization and (3) goodwill. We determine the useful lives of definite-lived intangible assets after considering specific facts and circumstances related to each intangible asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, and other economic facts; including competition and specific market conditions. Intangible assets that are deemed to have definite lives are amortized, primarily on a straight-line basis, over their estimated useful lives. Intangible assets that are deemed to have indefinite lives, including goodwill, are reviewed for impairment annually on the anniversary of the Pelican acquisition which is April 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment test for indefinite-lived intangibles, other than goodwill, consists of a comparison of the fair value of the intangible asset with its carrying amount. If the carrying amount exceeds the fair value, an impairment charge is recognized in an amount equal to that excess. Indefinite-lived intangible assets, such as goodwill, are not amortized. The Company tests the carrying amounts of goodwill for recoverability on an annual basis or when events or changes in circumstances indicate evidence a potential impairment exists, using a fair value based test. The Company performed a qualitative assessment during the annual impairment review for fiscal 2018 and concluded that it was more likely than not that the fair value of the Company’s single reporting unit is greater than its carrying amount. Therefore, the two-step goodwill impairment test for the reporting unit was not necessary at December 31, 2018 In-process research and development, or IPR&D, assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. IPR&D assets represent the fair value assigned to technologies that we acquire, which at the time of acquisition have not reached technological feasibility and have no alternative future use. During the period that the assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if we become aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval and the ability to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, we may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value (see Note 7). The Company performed a qualitative assessment during the annual impairment review for fiscal 2018 as of December 31, 2018 and concluded that it was more likely than not that the fair value of the Company’s IPR&D is greater than its carrying amount. Therefore, the two-step IPR&D impairment test for the reporting unit was not necessary at December 31, 2018 Deferred Revenue Deferred revenue is comprised of proceeds of $1.0 million received from CPRIT for which the costs have not been incurred or the conditions of the award have not been met and grant funds received from an economic development grant agreement with the City of San Antonio (“Economic Development Grant”) that we entered into on November 1, 2017. Under the Economic Development Grant, we received $0.2 million in state enterprise fund grants for the purpose of defraying costs toward the purchase of laboratory equipment. As part of the agreement, we will provide the city of San Antonio with a purchase money security interest in the equipment to secure the repayment of grant funds should we fail to perform under the terms and conditions of the agreement. Our obligations under the agreement include meeting certain employment levels for a period of not less than seven years commencing on or before December 31, 2017 and establishing Pelican’s corporate headquarters in San Antonio. The Economic Development Grant funds will be recognized as income upon the achievement of the performance criteria and determination that the cash is no longer refundable to the State of Texas. Contingent Consideration Consideration paid in a business combination may include potential future payments that are contingent upon the acquired business achieving certain milestones in the future (“contingent consideration”). Contingent consideration liabilities are measured at their estimated fair value as of the date of acquisition, with subsequent changes in fair value recorded in the consolidated statements of operations. The Company estimates the fair value of the contingent consideration as of the acquisition date using the estimated future cash outflows based on the probability of meeting future milestones. The milestone payments will be made upon the achievement of clinical and commercialization milestones as well as single low digit royalty payments and payments upon receipt of sublicensing income. Subsequent to the date of acquisition, the Company reassess the actual consideration earned and the probability-weighted future earn-out payments at each balance sheet date. Any adjustment to the contingent consideration liability will be recorded in the consolidated statements of operations. Contingent consideration liabilities expected to be settled within 12 months after the balance sheet date are presented in current liabilities, with the non-current portion recorded under long term liabilities in the consolidated balance sheets (see Note 4). Research and Development Research and development costs associated with developmental products not yet approved by the FDA as well as costs associated with bringing developmental products into advanced phase clinical trials as incurred. These costs consist primarily of pre-manufacturing and manufacturing drug costs, clinical trial execution, investigator payments, license fees, salaries, stock-based compensation and related personnel costs. Other costs include fees paid to consultants and outside service providers related to the development of the Company’s product candidates and other expenses relating to the design, development, and testing and enhancement of its product candidates. Impact of Recently Issued Accounting Standards: In November 2018, the FASB issued ASU 2018-18: Collaborative Arrangements In June 2018, the FASB issued ASU 2018-07: Compensation – Stock Compensation In June 2018, the FASB issued ASU No. 2018-08 Not-For-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) In August 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09),

Short-Term Investments

Short-Term Investments	12 Months Ended
	Dec. 31, 2018
Short-term Investments [Abstract]
Short-Term Investments	3 . Short-Term Investments Investments in certain securities may be classified into three categories: · Held-to-maturity - · Trading securities - · Available-for-sale - The Company reassesses the appropriateness of the classification of its investments at the end of each reporting period. The Company has determined that its debt securities should be classified as held-to-maturity as of December 31, 2018. We had no debt securities as of December 31, 2017. This classification was based upon management’s determination that it has the positive intent and ability to hold the securities until their maturity dates, as all of the investments mature within 3-6 months and the underlying cash invested in these securities is not required for current operations before the investments maturity. Investments consist of short-term FDIC insured certificates of deposit, commercial paper rated A1/P1 or above and corporate notes rated A and above carried at amortized cost using the effective interest method. The following summarizes information about short term investments at December 31, 2018 and 2017, respectively: Amortized Gross Estimated 2017 Certificates of deposit, commercial paper $ — $ — $ — 2018 Certificates of deposit, commercial paper $ 5,570,158 $ (131 ) $ 5,570,027 As of December 31, 2018, the estimated fair value of the investments was less than the amortized cost. Because management intends to hold the investments until their maturity dates, these unrealized losses were not recorded in the consolidated financial statements.

Acquisition of Pelican Therapeu

Acquisition of Pelican Therapeutics	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Acquisition of Pelican Therapeutics	4 . Acquisition of Pelican Therapeutics On April 28, 2017, the Company consummated the acquisition of 80% of the outstanding equity of Pelican, a related party, and Pelican became a majority owned subsidiary of the Company. Operations of Pelican are included in the consolidated statements of operations and comprehensive loss from the acquisition date. Pelican is a biotechnology company focused on the development and commercialization of monoclonal antibody and fusion protein-based therapies that are designed to activate the immune system. In exchange for 80% of the outstanding capital stock of Pelican on a fully diluted basis, the Company paid to the Pelican Stockholders that executed the Stock Purchase Agreement (the “Participating Pelican Stockholders”) an aggregate of $0.5 million minus certain liabilities (the “Cash Consideration”), and issued to the Participating Pelican Stockholders 133,106 shares of the Company’s restricted common stock representing 4.99% of the outstanding shares of our common stock on the date of the initial execution of the Purchase Agreement (the “Stock Consideration”). During the year ended December 31, 2018, the Cash Consideration of approximately $0.3 million was distributed to the Participating Pelican Stockholders and the remainder of approximately $0.2 million for certain Pelican liabilities not satisfied was recognized as other income in the Consolidated Statements of Operations and Comprehensive Loss. Under the agreement, the Company is also obligated to make future payments based on the achievement of certain clinical and commercialization milestones, as well as low single digit royalty payments and payments upon receipt of sublicensing income: $2.0 million upon Pelican’s dosing of the first patient in its first Phase 1 trial for an oncology indication; $1.5 million upon Pelican’s dosing of the first patient in its first Phase 2 trial for an oncology indication; $3.0 million upon successful outcome of the first Phase 2 trial for an oncology indication; $6.0 million upon Pelican’s dosing of the first patient in its first Phase 3 trial for an oncology indication; $3.0 million upon Pelican’s dosing of the first patient in its first Phase 3 trial for a non- oncology indication; $7.5 million upon successful outcome of the first Phase 3 trial for an oncology indication; $3.0 million upon successful outcome of the first Phase 3 trial for a non-oncology indication; $7.5 million upon acceptance of a Biologics License Application (BLA) submission for an oncology indication; $3.0 million upon acceptance of a BLA submission for a non-oncology indication; $7.5 million upon first product indication approval in the United States or Europe for an oncology indication; $3.0 million upon first product indication approval in the United States or Europe for a non-oncology indication. The fair value of these future milestone payments is reflected in the contingent consideration account under current liabilities with the non-current portion under long term liabilities on the balance sheet. The estimated fair value of the contingent consideration was determined using a probability-weighted income approach, at a discount of 7.2% based on the median yield of publicly traded non-investment grade debt of companies in the pharmaceutical industry. The Company performs an analysis on a quarterly basis and as of December 31, 2018, the Company determined the change in the estimated fair value of the contingent consideration was approximately $0.5 million and $0.2 million for the years ended December 31, 2018 and 2017, respectively. We have recorded the assets purchased and liabilities assumed at their estimated fair value in accordance with FASB ASC Topic 805: Business Combinations. The purchase price exceeded the fair value of the net assets acquired resulting in goodwill of approximately $2.2 million. The identifiable indefinite-lived intangible assets consists of in-process R&D of approximately $5.9 million. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company utilized corporate bond yield data observed in the bond market to develop the discount rate utilized in the cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions. Operations of the acquired entity are included in the consolidated statements of operations from the acquisition date. Fees and expenses associated with the acquisition were approximately $0.6 million for the twelve months ended December 31, 2017 and are reported in our general and administrative expense. The purchase price has been allocated to the assets and liabilities as follows: Aggregate consideration: Cash consideration $ 500,000 Stock consideration $ 1,052,000 Contingent consideration $ 2,385,000 Total Consideration $ 3,937,000 Purchase price allocation: Cash acquired $ 31,199 In-process R&D $ 5,866,000 Goodwill $ 2,189,338 Deferred tax liability $ (2,111,760 ) Net liabilities assumed $ (1,102,777 ) Fair value of non-controlling interest $ (935,000 ) Total purchase price $ 3,937,000 Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired and liabilities assumed. The goodwill resulting from this acquisition arises largely from synergies expected from combining the operations. The goodwill is not deductible for income tax purposes. In-process R&D assets are treated as indefinite-lived until the completion or abandonment of the associated R&D program, at which time the appropriate useful lives will be determined. The Company calculated the fair value of the non-controlling interest acquired in the acquisition as 20% of the equity interest of Pelican, adjusted for a minority interest discount. In May 2016, Pelican was awarded a $15.2 million CPRIT Grant from CPRIT for development of Pelican’s lead product candidate, PTX-35. The CPRIT Grant is expected to allow Pelican to develop PTX-35 through a 70-patient Phase 1 clinical trial. The Phase 1 clinical trial will be designed to evaluate PTX-35 in combination with other immunotherapies. The CPRIT Grant is subject to customary CPRIT funding conditions including a matching funds requirement where Pelican will match $0.50 for every $1.00 from CPRIT. Consequently, Pelican is required to raise $7.6 million in matching funds over the three year project. As of December 31, 2018, CPRIT has provided $8.3 million of the total $15.2 million grant. The remaining $6.9 million will become available in the third CPRIT fiscal year (June 2018 through May 2019). As of December 31, 2018, we have provided approximately $5.2 million funding to Pelican which includes matching CPRIT funds and we have $3.5 million remaining to provide for the third CPRIT fiscal year (June 2018 through May 2019). After its acquisition on April 28, 2017, Pelican contributed net revenue and net loss of approximately $1.5 million and $1.7 million, respectively, for the year ended December 31, 2017, which are included in the Company’s consolidated statement of operations and exclude acquisition and integration related expenses which are included in non-recurring and acquisition-related costs. The following unaudited pro forma information presents the combined results of operations for the year ended December 31, 2017, as if we had completed the Pelican acquisition at the beginning of fiscal 2017. The pro forma financial information is provided for comparative purposes only for the year ended December 31, 2017 and is not necessarily indicative of what actual results would have been had the acquisition occurred on the date indicated, nor does it give effect to synergies, cost savings, fair market value adjustments, immaterial amortization expense and other changes expected to result from the acquisition. Accordingly, the pro forma financial results do not purport to be indicative of consolidated results of operations as of the date hereof, for any period ended on the date hereof, or for any other future date or period. (in millions except per share value) December 31, 2017 (unaudited) Grant and licensing revenue $ 1.5 Net loss (12.8 ) Net loss: Non-controlling interest (0.6 ) Net loss attributable to Heat Biologics, Inc. $ (12.2 ) Net loss per share attributable to Heat Biologics, Inc.—basic and diluted $ (3.16 )

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2018
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following at: December 31, 2018 2017 Prepaid manufacturing expense $ 559,110 $ 1,551,597 Prepaid insurance 284,931 218,750 Other prepaid expenses 117,261 87,937 Other current assets 15 108,973 $ 961,317 $ 1,967,257

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment are recorded at cost and depreciated using the straight-line method over estimated useful lives ranging generally from five to seven years. Expenditures for maintenance and repairs are charged to expense as incurred. Property and equipment consisted of the following at: December 31, 2018 2017 Lab equipment $ 1,218,532 $ 645,433 Leasehold improvements 9,445 — Computers 38,589 41,333 Furniture and fixtures 58,146 55,883 Total 1,324,712 742,649 Accumulated depreciation (681,566 ) (455,758 ) Property and equipment, net $ 643,146 $ 286,891 Depreciation expense totaled $237,318 and $134,084 for the years ended December 31, 2018 and 2017, respectively.

Goodwill and In-process R&D

Goodwill and In-process R&D	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and In-process R&D	7. Goodwill and In-process R&D The following table provides a rollforward of the Company’s goodwill as of December 31, 2017 and 2018: Goodwill Goodwill from acquisition of Pelican $ 2,189,338 Balance at December 31, 2017 2,189,338 Purchase accounting adjustments — Balance at December 31, 2018 $ 2,189,338 The following table provides a rollforward of the Company’s in-process R&D as of December 31, 2017 and 2018: In-process R&D In-process R&D from acquisition of Pelican $ 5,866,000 Balance at December 31, 2017 5,866,000 Purchase accounting adjustments — Balance at December 31, 2018 $ 5,866,000 The Company performed a qualitative assessment for goodwill and IPR&D during the annual impairment review for fiscal 2018 as of December 31, 2018 and concluded that it was more likely than not that the fair value of the Company’s single reporting unit and IPR&D are greater than their carrying amount. Therefore, the two-step goodwill impairment test and the two-step IPR&D impairment test for the reporting unit was not necessary at December 31, 2018 and 2017, respectively.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities, Current [Abstract]
Accrued Expenses	8. Accrued Expenses Accrued expenses consist of the following at: December 31, 2018 2017 Accrued clinical trial expenses $ 919,750 $ 1,504,240 Compensation and related benefits 628,147 542,434 Patent fees 40,000 40,000 Deferred rent 7,854 27,457 Other expenses 82,300 162,300 $ 1,678,051 $ 2,276,431

License Agreements

License Agreements	12 Months Ended
	Dec. 31, 2018
License Agreements [Abstract]
License Agreements	9. License Agreements · University of Miami · Beginning in 2008, the Company has entered into various agreements with the University of Miami ( “ ” ImPACT ® “ ” · The Company agreed to make minimum royalty payments of $10,000 for three years beginning in 2010 that are due on the anniversary date of the agreement for License Agreement 97-14. Beginning in 2013, and thereafter for the life of the agreement, the minimum royalty payment shall be $20,000 due on the same date. In July 2016, the Company and UM entered into an amendment which replaced the milestone payment of $250,000 by approval of a BLA for the lung cancer vaccine with a payment of $500,000 upon approval of an NDA for a lung cancer vaccine covered by Patent Rights. · In August 2009, Heat I and UM entered into a second amendment ( “ ” · On February 18, 2011, Heat I entered into a license agreement (“SS114A”) with UM to obtain additional technology related to License Agreement 97-14. Heat I agreed to reimburse UM for all past patent costs of $37,381. As partial consideration for SS114A, Heat II agreed to grant back certain exclusive rights to UM. · On February 18, 2011, Heat I entered into a license agreement ( “ ” · On February 18, 2011, Heat I entered into a license agreement ( “ ” · In addition, Heat entered into an agreement for “ ” ImPACT ® ’ · On October 25, 2016, the Company entered into UM for the license and development of intellectual property related to its gp96 platform to target the Zika virus and other infectious diseases. As consideration for the rights granted in this license agreement the Company is obligated to pay UM an upfront license fee of $20,000 and nominal annual maintenance fees over the initial ten years that total $82,000 and increasing thereafter. The Company is obligated to pay royalties equal to a percentage (mid-single digits) of net sales of products covered by the patent-relayed rights, subject to reduction if additional licenses from third parties are required to commercialize licensed products · University of Miami - Pelican For each agreement, the Company agreed to make minimum royalty payments of $10,000 for three years beginning 2010 due on the anniversary date of the agreements to the University of Miami. Beginning in 2013, and thereafter for the life of the agreements, the minimum royalty payments shall be $20,000 due on the same date. License 03­31, 05­39 · Pelican is obligated to make milestone payments as follows: $150,000 due upon submission and approval of an IND and the completion of a Phase 1 clinical trial and $250,000 due upon the earlier of May 2022 or approval of an NDA. The Company has the right to terminate this Agreement without obligation for future unpaid milestones. · In August 2009, Pelican and UM entered into a second amendment ( “ ” · In February 2010, Pelican and UM entered into a third amendment ( “ ” · In October 2010, Pelican and UM entered into a fourth amendment ( “ ” License I­176 · On December 12, 2010, Pelican entered into another license agreement ( “ ” · In August 2012, Pelican and UM entered into a second amendment ( “ ” UMM­143 · On November 19, 2013, Pelican entered into another license agreement (“UMM­143”) with UM for an exclusive license of complimentary technology and patent rights. Pelican agreed to pay UM a license issue fee of $35,000, and agreed to make minimum royalty payments if the I­176 license agreement is terminated. No minimum royalty payments or milestone payments are due for any year in which the I­176 license agreement is in force. The Company has the right to terminate this Agreement without obligation for future unpaid milestones. · Other License Agreements · On April 12, 2011, Heat entered into a non-exclusive evaluation and biological material license agreement with a not-for-profit corporation for evaluation and production of vaccines. In consideration for the evaluation and commercial use license, Heat agreed to pay the not-for-profit corporation a fee of $5,000 and $50,000, respectively. Heat has the option to renew the license once the original term has expired. Milestone payments are due upon certain events agreed upon by Heat and the not-for-profit corporation. In December 2015, Heat amended the evaluation and biological material license agreement to add additional cell lines in exchange for a one-time payment of $1,000. · On August 30, 2010, Heat entered into an option agreement with the University of Michigan ( “ ” · In June 2016, the Company entered into an exclusive license agreement with Shattuck Labs, Inc. (“Shattuck”) pursuant to which the Company licensed certain provisional patent applications and know-how related to fusion proteins to treat cancer and other diseases that were not being developed by us. Shattuck paid the Company an initial license fee of $50,000 and is obligated to pay the Company fees upon its receipt of sublicensing income, achievement of certain milestones and royalties upon sales of commercial products. Inasmuch as the technology that the Company out-licensed is in the early stages of development and there is a low likelihood of success for any technology at such stage, there can be no assurance that any products will be developed by Shattuck or that we will derive any revenue from Shattuck. Future minimum royalty payments by the Company for licenses as of December 31, 2018 are as follows (in thousands): Year ended December 31, 2019 $ 74 2020 103 2021 228 2022 784 2023 74 Total $ 1,263

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2018
Stockholders' Equity
Stockholders' Equity	10. Stockholders’ Equity Authorized Capital Heat has authorized 10,000,000 shares of Preferred Stock (par value $0.0001) as of December 31, 2018 and 2017. As of December 31, 2018 and 2017, there were no outstanding shares of Preferred Stock. Heat had 100,000,000 shares of common stock (par value $0.0002) authorized as of December 31, 2018 and 2017. On January 19, 2018, Heat announced a reverse stock split of its shares of common stock at a ratio of 1-for-10. The reverse stock split took effect as of 11 p.m. ET on January 19, 2018, to trade on a post-split basis at the market open on January 22, 2018. During the Company’s annual shareholder meeting held June 29, 2017, shareholders approved the Company’s reverse stock split, and granted the board of directors the authority to implement and determine the exact split ratio. When the reverse stock split became effective, every 10 shares of the Company’s issued and outstanding common stock were combined into one share of common stock. Effecting the reverse stock split reduced the number of issued and outstanding common stock from approximately 42 million shares to approximately 4.2 million. Therefore, of the 100,000,000 common stock shares authorized, 32,492,144 and 4,200,310 common stock shares were issued and outstanding as of December 31, 2018 and 2017, respectively. Financings On January 18, 2018, the Company entered into a Common Stock Sales Agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, (“HCW”) as sales agent, pursuant to which the Company may sell from time to time, at its option, shares of its common stock, for the sale of up to $3.7 million of shares of the Company’s common stock and on March 15, 2018 filed with the SEC a prospectus supplement for an additional aggregate offering of up to $1.3 million shares of Common Stock. Sales of shares of Common Stock have been made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-221201) filed with the U.S. Securities and Exchange Commission (“SEC”), dated November 13, 2017. As of December 31, 2018, the Company sold an aggregate of 1,566,997 shares of common stock under the HCW Sales Agreement resulting in net proceeds of approximately $3.8 million. On May 7, 2018, the Company closed an underwritten public offering (the “Offering”) in which it issued and sold (i) 4,875,000 shares of common stock together with a number of common warrants to purchase 2,437,500 shares of its common stock, and (ii) 9,500,000 pre-funded warrants, with each pre-funded warrant exercisable for one share of common stock, together with a number of common warrants to purchase 4,750,000 shares of its common stock. The public offering price was $1.44 per share of common stock, $1.43 per pre-funded warrant and $0.01 per common warrant. The net proceeds to the Company were approximately $18.8 million, net of underwriting discounts and commissions and other estimated offering expenses. The common stock warrants expire five years after date of issuance and have an exercise price of $1.584 per share. As of December 31, 2018, 3,054,667 common stock warrants have been exercised for an additional $4.8 million of proceeds to the Company and all pre-funded warrants have been exercised. In connection with the offering the Company entered into an underwriting agreement, dated May 2, 2018 with A.G.P./Alliance Global Partners (A.G.P.), as representative of the underwriters. The Underwriting Agreement contained customary representations, warranties, and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. On November 26, 2018, the Company closed an underwritten public offering in which it issued and sold 8,000,000 shares of the Company’s common stock together with warrants to purchase 4,000,000 shares of the Company’s common stock at a combined price to the public of $1.50. The warrants have an exercise price of $1.65, are exercisable upon issuance and expire five years from the date of issuance. In addition, the underwriter exercised the over-allotment option to purchase an additional 1,200,000 shares of common stock and warrants to purchase 600,000 shares of common stock. Net proceeds to Heat from this offering are approximately $12.7 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Heat. A.G.P./Alliance Global Partners acted as the sole book-running manager for the offering. During 2016 the Company had entered into an at-the-market Issuance Sales Agreement with FBR Capital Markets Co. pursuant to which it has sold shares of its common stock through FBR by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on or through the NASDAQ Capital Market, the existing trading market for the Company’s common stock, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices, and/or any other method permitted by law. Sales of shares of common stock have been made pursuant to the Company’s shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission (“SEC”), the base prospectus, dated October 23, 2014, filed as part of such registration statement and the prospectus supplement, dated August 15, 2016. FBR was entitled to compensation at a fixed commission rate up to 3.0% of the gross proceeds per share sold through it as sales agent under the sales agreement. For the year ended December 31, 2017, the Company sold 234,858 shares of common stock under the Sales Agreement resulting in net proceeds of approximately $2.3 million after FBR’s commission and other expenses. On November 3, 2017, the Company terminated its At Market Issuance Sales Agreement with FBR. On March 28, 2017, the Company sold pursuant to the terms of an Underwriting Agreement (the “Underwriting Agreement”) the Company sold pursuant to the terms of an Underwriting Agreement (the “Underwriting Agreement (“Aegis”), as representative of the several underwriters named therein (the “Underwriters”), 500,000 shares of the Company’s common stock and 75,000 additional shares of the common stock to cover over-allotments at an offering price of $8.00 per share, (the “March Offering”). The net proceeds to the Company from the March Offering were approximately $4.1 million, after deducting underwriting discounts, commissions, and other third party offering expenses. The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. In November 2017, the Company sold pursuant to the terms of an Underwriting Agreement (the “Underwriting Agreement”) the Company sold pursuant to the terms of an Underwriting Agreement (the “Underwriting Agreement (“Aegis”), as representative of the several underwriters named therein (the “Underwriters”), 581,395 shares of the Company’s common stock, and 39,255 additional shares of the common stock to cover over-allotments at an offering price of $4.30 per share, (the “Offering”). The net proceeds to the Company from the Offering were approximately $2.4 million, after deducting underwriting discounts, commissions, and other third party offering expenses. The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and termination provisions. Restricted Stock In January 2018, the Company granted 60,375 restricted stock units to the employees of the Company in which 25%, (15,092 restricted stock units) vested immediately and the remainder will vest on each anniversary of the grant date over a three-year period contingent on continued employment with the Company. Additionally, the Company issued 35,989 restricted stock units to certain employees who chose to use a portion of their 2017 monetary bonus in lieu of restricted stock units that vested immediately, but are subject to a one year restriction on transferability. In January 2017, the Company granted 42,850 restricted stock units to the employees of the Company in which 25%, (10,713 restricted stock units) vested immediately and the remainder will vest on each anniversary of the grant date over a three-year period contingent on continued employment with the Company. The Company recognized $318,186 and $169,517 in stock-based compensation expense for employees related to restricted stock awards during the years ended December 31, 2018 and 2017. In January 2018, the Company granted 3,250 restricted stock units to nonemployees in exchange for services in which 25%, (812 restricted stock units) vested immediately and the remainder will vest on each anniversary of the grant date over a three-year period contingent on continued association with the Company. The Company recognized stock-based compensation related to the grant of restricted stock units to nonemployees totaling $6,369. There were no restricted stock units granted to nonemployees during 2017. The Company recognized stock-based compensation related to issuance of restricted stock to nonemployees in exchange for services totaling $0 and $31,000 for the years ended December 31, 2018 and 2017, respectively. Common Stock Warrants In connection with the November 26, 2018 public offering, the Company issued 4,600,000 common stock warrants of which are exercisable for one share of common stock. The common stock warrants have an exercise price of $1.65 per share and expire five years from the issuance date. The warrants have been accounted for as equity instruments. The fair value of the common stock warrants of approximately $5.6 million at the date of issuance was estimated using the Black-Scholes Merton model which used the following inputs: term of 5 years, risk free rate of 2.89%, 0% dividend yield, volatility of 133.26%, and share price of $1.42 per share based on the trading price of the Company’s common stock. In connection with the May 7, 2018 public offering, the Company issued 9,500,000 pre-funded warrants and 7,187,500 common stock warrants each of which are exercisable for one share of common stock. The pre-funded warrants had an exercise price of $0.01 per share and as of December 31, 2018 all pre-funded warrants have been exercised. The common stock warrants have an exercise price of $1.584 per share and expire five years from the issuance date. As of December 31, 2018, 3,054,667 common stock warrants have been exercised. The warrants have been accounted for as equity instruments. The fair value of the common stock warrants of approximately $7.8 million at the date of issuance was estimated using the Black-Scholes Merton model which used the following inputs: term of 5 years, risk free rate of 2.78%, 0% dividend yield, volatility of 124.14%, and share price of $1.30 per share based on the trading price of the Company’s common stock. In connection with the March 23, 2016 public offering, the Company issued warrants to purchase 682,500 shares of common stock with an exercise price of $10.00 per share that expire five years from the issuance date. In connection with the Company’s July 23, 2013 initial public offering, the Company issued warrants to the underwriters for 12,500 shares of common stock issuable at $125.00 per share which expired July 22, 2018. On March 10, 2011, the Company issued warrants to purchase shares of common stock to third parties in consideration for a private equity placement transaction of which 1,738 warrants remain outstanding. The warrants have an exercise price of $4.80 per share and expire ten years from the issuance date. During the year ended December 31, 2018, 3,054,667 common stock warrants have been exercised and 12,500 common stock warrants have expired. No warrants were issued or exercised during the same period in 2017. As of December 31, 2018 the Company has outstanding warrants to purchase 4,600,000 shares of common stock issuable at $1.65 per share, 4,132,833 shares of common stock issuable at $1.584 per share, 296,159 shares of common stock issuable at $10.00 per share; and warrants to purchase 1,738 shares of common stock issuable at $4.80 per share. These warrants do not meet the criteria required to be classified as liability awards and therefore are treated as equity awards. The Company has a total of 9,030,730 warrants outstanding at a weighted average exercise price of $1.89 to purchase its common stock as of December 31, 2018. These warrants are summarized as follows: Issuance Date Number of Shares Exercise Price Expiration Date 3/10/2011 1,738 $ 4.80 3/10/2021 3/23/2016 296,159 $ 10.00 3/23/2021 5/7/2018 4,132,833 $ 1.58 5/8/2023 11/26/2018 4,600,000 $ 1.65 11/26/2023 The following table summarizes the warrant activity of the Company’s common stock warrants: Common Stock Warrants Outstanding, December 31, 2016 310,397 Exercised — Expired — Outstanding, December 31, 2017 310,397 Issued 11,787,500 Exercised 3,054,667 Expired (12,500 ) Outstanding, December 31, 2018 9,030,730 Equity Compensation Plans 2009 Stock Incentive Plan In 2009, the Company adopted the 2009 Stock Option Plan of Heat Biologics, Inc. (the “2009 Plan”), under which stock options to acquire 21,739 common shares could be granted to key employees, directors, and independent contractors. Under the 2009 Plan, both incentive and non-qualified stock options could be granted under terms and conditions established by the Board of Directors. The exercise price for incentive stock options was the fair market value of the related common stock on the date the stock option was granted. Stock options granted under the 2009 Plan generally have terms of 10 years and have various vesting schedules. The Company amended the 2009 Stock Option Plan and all related addendum agreements in April 2011. This second amendment increased the number of shares available for issuance from 21,739 to 65,217. The Company amended the 2009 Plan to increase the number of shares available for issuance to 86,957. As of December 31, 2018 and 2017, there were 23,799 and 24,042 stock options outstanding under the 2009 Plan, respectively. 2014 Stock Incentive Plan In June 2014, the stockholders approved the 2014 Stock Option Plan of Heat Biologics, Inc. (the “2014 Plan”), under which the Company is authorized to grant 50,000 awards in the form of both incentive and non-qualified stock options, restricted stock, stock appreciation rights and other stock based awards with terms established by the Compensation Committee of the Board of Directors which has been appointed by the Board of Directors to administer the 2014 Plan. In 2015, the stockholders approved an amendment to the Plan to increase the number of shares by 60,000 and in 2016, the stockholders approved an amendment that allowed the Company to grant up to 300,000 awards in total. As of December 31, 2018 and 2017, there were 263,484 and 232,768 stock options outstanding under the 2014 Plan, respectively. 2017 Stock Incentive Plan In June 2017, the stockholders approved the 2017 Stock Incentive Plan of Heat Biologics, Inc. (the “2017 Plan”), under which the Company is authorized to grant 500,000 awards in the form of both incentive and non-qualified stock options, restricted stock, stock appreciation rights and other stock based awards with terms established by the Compensation Committee of the Board of Directors which has been appointed by the Board of Directors to administer the 2017 Plan. As of December 31, 2018 and 2017 there were 234,540 and 10,000 stock options outstanding under the 2017 Plan, respectively. 2018 Stock Incentive Plan In October 2018, the stockholders approved the 2018 Stock Incentive Plan of Heat Biologics, Inc. (the “2018 Plan”), under which the Company is authorized to grant 4,000,000 awards in the form of both incentive and non-qualified stock options, restricted stock, stock appreciation rights and other stock based awards with terms established by the Compensation Committee of the Board of Directors which has been appointed by the Board of Directors to administer the 2018 Plan. As of December 31, 2018 there were no stock options outstanding under the 2018 Plan. There are 4,260,215 stock options remaining available for grant under the Plans. The following table summarizes the components of the Company’s stock-based compensation included in net loss: For the years ended December 31, 2018 2017 Employee stock options $ 443,684 $ 474,251 Non-employee stock options 20,420 14,362 Employee stock awards 318,186 169,517 Non-employee stock awards 6,369 31,000 $ 788,659 $ 689,130 Stock Options The fair value of each stock option is estimated on the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions for stock options granted during the years ended: December 31, 2018 2017 Dividend yield 0.0 % 0.0 % Expected volatility 83.63-121.81 % 76.35-79.08 % Risk-free interest rate 2.32-2.98 % 1.86-2.26 % Expected term (years) 5.1-6.3 5.8-7.8 The risk-free interest rate is based on U.S. Treasury interest rates at the time of the grant whose term is consistent with the expected life of the stock options. The Company used an average historical stock price volatility based on an analysis of reported data for a peer group of comparable companies that have issued stock options with substantially similar terms, as the Company had limited to no trading history for its common stock. Expected term represents the period that the Company’s stock option grants are expected to be outstanding. The Company elected to utilize the “simplified” method to estimate the expected term. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. Expected dividend yield was considered to be 0% in the option pricing formula since the Company had not paid any dividends and had no plans to do so in the future. As required by ASC 718, the Company reviews recent forfeitures and stock compensation expense. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Additionally, the Company conducts a sensitivity analysis. Based on these evaluations the Company currently does not apply a forfeiture rate. The Company recognized $464,104 and $488,613 in stock-based compensation expense for the years ended December 31, 2018 and 2017, respectively, for the Company’s stock option awards. The following tables summarize the stock option activity for the year ended December 31, 2018: Shares Weighted Average Exercise Price Outstanding, December 31, 2017 266,810 $ 19.57 Granted 221,410 $ 3.57 Exercised — $ — Forfeited/Expired (22,917 ) $ 26.97 Outstanding, December 31, 2018 465,303 $ 11.60 The weighted average grant-date fair value of stock options granted during the years ended December 31, 2018 and 2017 was $2.65 and $5.33, respectively. The following table summarizes information about stock options outstanding at December 31, 2018: Options Outstanding Options Vested and Exercisable Balance as of 12/31/2018 Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Balance as of 12/31/2018 Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price 465,303 8.17 $11.60 198,957 7.21 $20.48 As of December 31, 2018, the unrecognized stock-based compensation expense related to unvested stock options was approximately $2.3 million that is expected to be recognized over a weighted average period of approximately 11.0 months. Total stock-based compensation expense including restricted stock, stock options, and common stock was $788,659 and $689,130 for the years ended December 31, 2018 and 2017, respectively.

Income Tax

Income Tax	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Income Tax	11. Income Tax Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In accordance with FASB ASC 740, Accounting for Income Taxes The components of income tax expense (benefit) attributable to continuing operations are as follows: 2018 2017 Current Expense: Federal $ — $ — State — — Foreign — — — — Deferred Expense: Federal $ (985,488 ) $ (762,580 ) State — (46,960 ) Foreign — — Total $ (985,488 ) $ (809,540 ) The differences between the company’s income tax expense attributable to continuing operations and the expense computed at the 21 % United States statutory income tax rate were as follows: 2018 2017 Federal income tax expense at statutory rate: $ (3,577,000 ) $ (4,495,000 ) Increase (reduction) in income tax resulting from: State Income Taxes (207,000 ) (194,000 ) Foreign Rate Differential (17,000 ) (16,000 ) Nondeductible Expenses 7,000 9,000 Prior Period True-Up - Pelican 208,000 — Research & Development Credit (763,000 ) (409,000 ) Stock Based Compensation 60,000 84,000 Acquisition Costs — 96,000 Reserve for Loss Carryforwards Limited by Sec. 382 22,000 (541,000 ) Tax Reform Impact — (8,024,000 ) Other 25,512 45,460 Increase (Decrease) in Valuation Allowance 3,256,000 (3,445,000 ) $ (985,488 ) $ (809,540 ) The tax effects of temporary differences and operating loss carryforwards that gave rise to significant portions of the deferred tax assets and deferred tax liabilities were as follows at December 31, 2018 and December 31, 2017: 2018 2017 Deferred tax assets: Net Operating Loss Carryfowards $ 18,731,555 $ 15,117,487 R&D Credits 2,729,737 1,966,964 Stock Compensation 744,506 629,447 Contingent Consideration 713,259 599,343 Other Accrued Expenses — 128,522 Deferred tax assets 22,919,057 18,441,763 Deferred tax liabilities: Property, plant and equipment, primarily due to differences in depreciation (127,140 ) (26,307 ) Other Accrued Expenses (11,926 ) — Intangible Assets (1,302,220 ) (1,302,220 ) Deferred tax liabilities (1,441,286 ) (1,328,527 ) Valuation allowance (21,794,504 ) (18,415,456 ) Net deferred tax assets (liabilities) $ (316,733 ) $ (1,302,220 ) At December 31, 2018 and December 31, 2017, the Company evaluated all significant available positive and negative evidence, including the existence of losses in recent years and management’s forecast of future taxable income, and, as a result, determined it was more likely than not that federal and state deferred tax assets, including benefits related to net operating loss carryforwards, would not be realized. The valuation allowance was increased from $18,415,456 at December 31, 2017 to $21,794,504 at December 31, 2018. Net Operating Losses created in years beginning after 2017 now only offset 80% of Taxable Income but no longer have a 20 year expiration. As such, NOL’s created after 2017 can be used to offset indefinite lived liabilities up to 80%. This change in tax law created a reduction of the deferred tax liability by $985,488 during 2018. At December 31, 2018, the Company has federal net operating loss carryforwards of approximately $84,517,142, including $3,027,284 acquired from Pelican Therapeutics, which are available to offset future taxable income. However, due to potential Section 382 limitations (discussed in further detail below) a reserve has been set up for the Pelican Therapeutics NOL of $(2,344,952). The federal net operating loss carryforwards begin to expire in 2029. The Company has various state net operating loss carryforwards totaling approximately $73,861,907 including $2,922,000 from Pelican Therapeutics, which are available to offset future state taxable income. State net operating losses begin to expire in 2024. The Company has various foreign net operating loss carryforwards of approximately $122,605. The foreign net operating loss carryforwards are carried forward indefinitely. Because the Company has incurred cumulative net operating losses since inception, all tax years remain open to examination by U.S. federal, state, and foreign income tax authorities. In accordance with FASB ASC 740, Accounting for Income Taxes The Company files income tax returns in the United States, various state and foreign jurisdictions. The Company is subject to examination by taxing authorities for the tax years ended December 31, 2009 through 2017. Potential 382 Limitation The Company’s ability to utilize its net operating loss (NOL) and research and development (R&D) credit carryforwards may be substantially limited due to ownership changes that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL and R&D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an “ownership change,” as defined by Section 382 of the Code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percent of the outstanding stock of a company by certain stockholders or public groups. The Company has not completed a study to assess whether one or more ownership changes have occurred since the Company became a loss corporation under the definition of Section 382. If the Company has experienced an ownership change, utilization of the NOL or R&D credit carryforwards would be subject to an annual limitation, which is determined by first multiplying the value of the Company’s stock at the time of the ownership change by the applicable long-term, tax-exempt rate, and then could be subject to additional adjustments, as required. Any such limitation may result in the expiration of a portion of the NOL or R&D credit carryforwards before utilization. Until a study is completed and any limitation known, no amounts are being considered as an uncertain tax position or disclosed as an unrecognized tax benefit under ASC-740. Any carryforwards that expire prior to utilization as a result of such limitations will be removed from deferred tax assets with a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, it is not expected that any possible limitation will have an impact on the results of operations of the Company.

Non-Controlling Interest

Non-Controlling Interest	12 Months Ended
	Dec. 31, 2018
Noncontrolling Interest [Abstract]
Non-Controlling Interest	12. Non-Controlling Interest In October 2018, Heat entered into an agreement with the University of Miami (“UM”) whereby UM exchanged its shares of stock in Heat’s subsidiaries, Heat I, Inc. and Pelican Therapeutics, Inc. (“Pelican”), a related party prior to acquisition. Pelican

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Related Party Transactions
Related Party	13. Related Party Transactions The Company compensates its board members. Board members received cash compensation between approximately $61,500 and $221,000 and $77,000 and $242,000, for services rendered during 2018 and 2017, respectively. Board members also received equity compensation. The Company acquired 80% of the outstanding equity of Pelican, a related party, during the year ended December 31, 2017, see Note 4; and an additional 5% during the year ended December 31, 2018 see Note 12.

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share	14. Net Loss Per Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options and warrants that are computed using the treasury stock method. For the years ended December 31, 2018 and 2017, all of the Company’s common stock options, unvested restricted stock units and warrants are anti-dilutive and therefore have been excluded from the diluted calculation. The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.: For the years ended December 31, 2018 2017 Net loss $ (16,591,293 ) $ (12,409,866 ) Net loss - Non-controlling interest (857,439 ) (568,195 ) Net loss attributable to Heat Biologics, Inc. $ (15,733,854 ) $ (11,841,671 ) Weighted-average number of common shares used in net loss per share attributable to common stockholders —basic and diluted 17,485,461 3,845,342 Net loss per share attributable to Heat Biologics, Inc —basic and diluted $ (0.90 ) $ (3.08 ) The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: For the years ended December 31, 2018 2017 Outstanding stock options 465,303 266,810 Unvested restricted stock units 56,520 21,779 Outstanding common stock warrants 9,030,730 310,397

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies During 2014, the Company entered into a five-year lease for a total of 5,979 square feet. The lease expires September 30, 2019 and the Company is currently in the process of evaluating its operations to determine the proper space required for its current operations, as well as that there are spaces available sufficient for any future expansion requirements should the need arise. Rent expense was $ Years ending December 31, 2019 309,729 2020 115,580 2021 118,158 2022 120,736 2023 20,194 Total $ 684,397

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Heat Biologics, Inc. and its subsidiaries, Heat Biologics I, Inc. (“Heat I”) Heat Biologics III, Inc. (“Heat III”), Heat Biologics IV, Inc. (“Heat IV”), Heat Biologics GmbH, Heat Biologics Australia Pty Ltd, and Zolovax, Inc. Additionally, beginning April 28, 2017 the accompanying consolidated financials include Pelican. As of December 31, 2018 there was no activity for Delphi Therapeutics, Inc. or Scorpion Biosciences, Inc. The functional currency of the entities located outside the United States of America (the foreign entities) is the applicable local currency of the foreign entities. Assets and liabilities of the foreign entities are translated at period-end exchange rates. Statement of operations accounts are translated at the average exchange rate during the period. The effects of foreign currency translation adjustments are included in other comprehensive loss, which is a component of accumulated other comprehensive loss in stockholders’ equity. All significant intercompany accounts and transactions have been eliminated in consolidation. At December 31, 2018 and 2017, Heat held 100% and 92.5% controlling interest respectively in Heat I. The December 31, 2018 year-end financials include 85% controlling interest in Pelican and the December 31, 2017 year-end financials include 80% controlling interest in Pelican as of April 28, 2017. Heat accounts for its less than 100% interest in the consolidated financial statements in accordance with U.S. GAAP. Accordingly, the Company presents non-controlling interest as a component of stockholders’ equity on its consolidated balance sheets and reports non-controlling interest net loss under the heading “net loss – non-controlling interest” in the consolidated statements of operations and comprehensive loss.
Liquidity and Capital Resources	Liquidity and Capital Resources The Company has an accumulated deficit of approximately $84.6 million as of December 31, 2018 and a net loss of approximately $16.6 million for the twelve months ended December 31, 2018 and has not generated significant revenue or positive cash flows from operations. The Company expects to incur significant expenses and continued losses from operations for the foreseeable future. The Company expects its expenses to increase in connection with its ongoing activities, particularly as the Company continues its research and development and advances its clinical trials of, and seek marketing approval for, its product candidates and as the Company continues to fund the Pelican matching funds required in order to access the CPRIT Grant. In addition, if the Company obtains marketing approval for any of its product candidates, the Company expects to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, the Company will need to obtain substantial additional funding in connection with its continuing operations. Adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or any future commercialization efforts. To meet its capital needs, the Company intends to continue to consider multiple alternatives, including, but not limited to, additional equity financings such as sales of its common stock under at-the-market offerings, if available, debt financings, partnerships, collaborations and other funding transactions. This is based on the Company’s current estimates, and the Company could use its available capital resources sooner than it currently expects. The Company is continually evaluating various cost-saving measures in light of its cash requirements in order to focus resources on its product candidates. The Company will need to generate significant revenues to achieve profitability, and it may never do so. As of December 31, 2018, the Company had approximately $27.7 million in cash, cash equivalents and short term investments and believes it has the ability to fund its operations within one year from the date these financial statements are issued.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, useful lives of fixed assets, contingent consideration, income taxes and stock-based compensation. Actual results may differ from those estimates.
Segments	Segments The Company has one reportable segment – the development of immunotherapies designed to activate and expand a patient’s T-cell mediated immune system against cancer.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash The Company considers all cash and other highly liquid investments with initial maturities from the date of purchase of three months or less to be cash and cash equivalents. The Company had a restricted cash balance of $0 and $2,292 at December 31, 2018 and 2017, respectively.
Concentration of Credit Risk	Concentration of Credit Risk At times, cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurable limits. The Company has never experienced any losses related to these balances. As of December 31, 2018 and 2017, cash amounts in excess of $250,000 were not fully insured. The uninsured cash balance as of December 31, 2018 was $21,904,251. The Company does not believe it is exposed to significant credit risk on cash and cash equivalents.
Property and Equipment	Property and Equipment Property and equipment are stated at cost and are capitalized. Depreciation is calculated using the straight-line method and is based on estimated useful lives of five years for lab equipment and computer equipment, and seven years for furniture and fixtures.
Net Loss per Share	Net Loss per Share Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding during each year. Fully diluted net loss per share is computed using the weighted average number of common shares and dilutive securities outstanding during each year. Dilutive securities having an anti-dilutive effect on diluted loss per share are excluded from the calculation.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other payables approximate fair value due to their short maturities. As a basis for determining the fair value of certain of the Company’s financial instruments, the Company utilizes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level I – Observable inputs such as quoted prices in active markets for identical assets or liabilities. Level II – Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level III – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The Company's cash equivalents are classified within Level I of the fair value hierarchy. As of December 31, 2018 and 2017, the fair values of cash, accounts payable, and accrued expenses approximated their carrying values because of the short-term nature of these assets or liabilities. The Company’s short-term investments consist of Level I securities which are comprised of highly liquid money market funds. The estimated fair value of the short-term investments was based on quoted market prices. There were no transfers between fair value hierarchy levels during the years ended December 31, 2018 or 2017. The fair value of financial instruments measured on a recurring basis is as follows: As of December 31, 2018 Description Total Level 1 Level 2 Level 3 Assets: Short-term investments $ 5,570,027 $ 5,750,027 — — Liabilities: Contingent consideration 3,105,225 — — $ 3,105,225 As of December 31, 2017 Description Total Level 1 Level 2 Level 3 Liabilities: Contingent consideration $ 2,609,289 — — $ 2,609,289 The following table summarizes the change in fair value, as determined by Level 3 inputs, for all assets and liabilities using unobservable Level 3 inputs for the year ended December 31, 2018: Contingent Consideration Balance at December 31, 2016 $ — Acquisition of Pelican 2,385,000 Change in fair value 224,289 Balance at December 31, 2017 2,609,289 Change in fair value 495,936 Balance at December 31, 2018 $ 3,105,225 The change in the fair value of the contingent consideration of $495,936 and $224,289 for the years ended December 31, 2018 and 2017 was primarily due to the effect of the change in discount rate, probability of achieving milestones, and passage of time on the fair value measurement. Adjustments associated with the change in fair value of contingent consideration are included in the Company’s consolidated statement of operations and comprehensive loss. The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements of contingent consideration classified as Level 3 as of December 31, 2018: Valuation Significant Weighted Average Contingent Consideration Probability weighted Milestone dates 2019-2025 Discount rate 13.82% to 3.66% Probability of occurrence 23% to 86%
Income Tax	Income Tax Income taxes are accounted for using the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the carrying amounts of assets and liabilities and their respective tax bases, operating loss carryforwards, and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. In accordance with FASB ASC 740, Accounting for Income Taxes On December 22, 2017, the Tax Cuts and Jobs Act (“Tax Act”) was signed into law. The Tax Act lowered the Federal corporate tax rate from 34% to 21% and made numerous other tax law changes. The Company has measured deferred tax assets at the enacted tax rate expected to apply when these temporary differences are expected to be realized or settled. Under the guidance of SAB 118, the Company is required to recognize the effect of tax law changes in the period of enactment. Reasonable estimates were made based on the Company’s analysis of the Tax Act. These provisional amounts were adjusted during 2018 when additional information was obtained with no material adjustments.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for stock-based compensation arrangements with employees and non-employee directors using a fair value method that requires the recognition of compensation expense for costs related to all stock-based payments, including stock options and restricted stock units. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The fair value of restricted stock units is estimated based on the closing price of the Company's stock on the date of grant, and for the purposes of expense recognition, the total new number of shares expected to vest is adjusted for estimated forfeitures. Stock-based compensation costs are based on the fair value of the underlying option calculated using the Black-Scholes-Merton option pricing model on the date of grant for stock options and are recognized as expense on a straight-line basis over the requisite service period, which is the vesting period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating stock price volatility, forfeiture rates and expected term. The expected volatility rates are estimated based on the actual volatility of comparable public companies over the expected term. The expected term for the years ended December 31, 2018 and 2017 represents the average time that options are expected to be outstanding based on the average of the vesting term and the contractual term of the option. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying a cash dividend in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards. The measurement of nonemployee share-based compensation is subject to periodic adjustments as the underlying equity instruments vest and is recognized as an expense in the period over which services are received.
Net loss attributable to non-controlling interests	Net loss attributable to non-controlling interests Net loss attributable to non-controlling interests is the result of the Company's consolidation of subsidiaries of which it does not own 100%. In October 2018, the Company entered into an agreement with the University of Miami (“UM”) whereby UM exchanged its shares of stock in the Company’s subsidiaries, Heat I, Inc. and Pelican, a related party prior to acquisition, for 35,000 shares of the Company’s common stock. The stock exchange Pelican
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company has adopted on a modified retrospective basis Accounting Standards Codification (ASC) Topic 606. The Company’s sole source of revenue is grant revenue related to the CPRIT contract, which is being accounted for under ASC 606. ASC 606 introduces a new framework for analyzing potential revenue transactions by identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations in the contract, and recognizing revenue when (or as) the Company satisfies a performance obligation. The performance obligations of the Contract include developing a human TNFRSF25 agonist antibody for use in cancer patients through research and development efforts and a noncommercial license from CPRIT-funded research to CPRIT and other government agencies and institutions of higher education in Texas. Management has concluded that the license and R&D services should be combined into a single performance obligation as both are highly interdependent - a license cannot be effectively granted without the corresponding research basis and CPRIT cannot benefit from the license without the R&D services and are therefore not capable of being distinct. The CPRIT grant covers a three-year period from June 1, 2017 through May 31, 2019, for a total grant award of up to $15.2 million. CPRIT advances grant funds upon request by the Company consistent with the agreed upon amounts and schedules as provided in the contract. The first tranche of funding of $1.8 million was received in May 2017, and a second tranche of funding of $6.5 million was received in October 2017. The next tranche of funding is expected to be requested and received in early 2019. Funds received are reflected in deferred revenue as a liability until revenue is earned. Grant revenue is recognized when qualifying costs are incurred. As of December 31, 2018, the deferred revenue balance was $1.0 million with $7.3 million recognized as revenue since contract inception.
Business Combinations	Business Combinations We account for acquisitions using the acquisition method of accounting, which requires that all identifiable assets acquired and liabilities assumed be recorded at their estimated fair values. The excess of the fair value of purchase consideration over the fair values of identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions. Critical estimates in valuing certain intangible assets include but are not limited to future expected cash flows from acquired patented technology. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Other estimates associated with the accounting for acquisitions may change as additional information becomes available regarding the assets acquired and liabilities assumed (see Note 4).
Goodwill and In-Process Research and Development	Goodwill and In-Process Research and Development We classify intangible assets into three categories: (1) intangible assets with definite lives subject to amortization, (2) intangible assets with indefinite lives not subject to amortization and (3) goodwill. We determine the useful lives of definite-lived intangible assets after considering specific facts and circumstances related to each intangible asset. Factors we consider when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, and other economic facts; including competition and specific market conditions. Intangible assets that are deemed to have definite lives are amortized, primarily on a straight-line basis, over their estimated useful lives. Intangible assets that are deemed to have indefinite lives, including goodwill, are reviewed for impairment annually on the anniversary of the Pelican acquisition which is April 1, or more frequently if events or changes in circumstances indicate that the asset might be impaired. The impairment test for indefinite-lived intangibles, other than goodwill, consists of a comparison of the fair value of the intangible asset with its carrying amount. If the carrying amount exceeds the fair value, an impairment charge is recognized in an amount equal to that excess. Indefinite-lived intangible assets, such as goodwill, are not amortized. The Company tests the carrying amounts of goodwill for recoverability on an annual basis or when events or changes in circumstances indicate evidence a potential impairment exists, using a fair value based test. The Company performed a qualitative assessment during the annual impairment review for fiscal 2018 and concluded that it was more likely than not that the fair value of the Company’s single reporting unit is greater than its carrying amount. Therefore, the two-step goodwill impairment test for the reporting unit was not necessary at December 31, 2018 In-process research and development, or IPR&D, assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development projects. IPR&D assets represent the fair value assigned to technologies that we acquire, which at the time of acquisition have not reached technological feasibility and have no alternative future use. During the period that the assets are considered indefinite-lived, they are tested for impairment on an annual basis, or more frequently if we become aware of any events occurring or changes in circumstances that indicate that the fair value of the IPR&D assets are less than their carrying amounts. If and when development is complete, which generally occurs upon regulatory approval and the ability to commercialize products associated with the IPR&D assets, these assets are then deemed definite-lived and are amortized based on their estimated useful lives at that point in time. If development is terminated or abandoned, we may have a full or partial impairment charge related to the IPR&D assets, calculated as the excess of carrying value of the IPR&D assets over fair value (see Note 7). The Company performed a qualitative assessment during the annual impairment review for fiscal 2018 as of December 31, 2018 and concluded that it was more likely than not that the fair value of the Company’s IPR&D is greater than its carrying amount. Therefore, the two-step IPR&D impairment test for the reporting unit was not necessary at December 31, 2018
Deferred Revenue	Deferred Revenue Deferred revenue is comprised of proceeds of $1.0 million received from CPRIT for which the costs have not been incurred or the conditions of the award have not been met and grant funds received from an economic development grant agreement with the City of San Antonio (“Economic Development Grant”) that we entered into on November 1, 2017. Under the Economic Development Grant, we received $0.2 million in state enterprise fund grants for the purpose of defraying costs toward the purchase of laboratory equipment. As part of the agreement, we will provide the city of San Antonio with a purchase money security interest in the equipment to secure the repayment of grant funds should we fail to perform under the terms and conditions of the agreement. Our obligations under the agreement include meeting certain employment levels for a period of not less than seven years commencing on or before December 31, 2017 and establishing Pelican’s corporate headquarters in San Antonio. The Economic Development Grant funds will be recognized as income upon the achievement of the performance criteria and determination that the cash is no longer refundable to the State of Texas.
Contingent Consideration	Contingent Consideration Consideration paid in a business combination may include potential future payments that are contingent upon the acquired business achieving certain milestones in the future (“contingent consideration”). Contingent consideration liabilities are measured at their estimated fair value as of the date of acquisition, with subsequent changes in fair value recorded in the consolidated statements of operations. The Company estimates the fair value of the contingent consideration as of the acquisition date using the estimated future cash outflows based on the probability of meeting future milestones. The milestone payments will be made upon the achievement of clinical and commercialization milestones as well as single low digit royalty payments and payments upon receipt of sublicensing income. Subsequent to the date of acquisition, the Company reassess the actual consideration earned and the probability-weighted future earn-out payments at each balance sheet date. Any adjustment to the contingent consideration liability will be recorded in the consolidated statements of operations. Contingent consideration liabilities expected to be settled within 12 months after the balance sheet date are presented in current liabilities, with the non-current portion recorded under long term liabilities in the consolidated balance sheets (see Note 4).
Research and Development	Research and Development Research and development costs associated with developmental products not yet approved by the FDA as well as costs associated with bringing developmental products into advanced phase clinical trials as incurred. These costs consist primarily of pre-manufacturing and manufacturing drug costs, clinical trial execution, investigator payments, license fees, salaries, stock-based compensation and related personnel costs. Other costs include fees paid to consultants and outside service providers related to the development of the Company’s product candidates and other expenses relating to the design, development, and testing and enhancement of its product candidates.
Impact of Recently Issued Accounting Standards	Impact of Recently Issued Accounting Standards: In November 2018, the FASB issued ASU 2018-18: Collaborative Arrangements In June 2018, the FASB issued ASU 2018-07: Compensation – Stock Compensation In June 2018, the FASB issued ASU No. 2018-08 Not-For-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805) In August 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09),

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of Fair Value of Financial Instruments Measurements	The fair value of financial instruments measured on a recurring basis is as follows: As of December 31, 2018 Description Total Level 1 Level 2 Level 3 Assets: Short-term investments $ 5,570,027 $ 5,750,027 — — Liabilities: Contingent consideration 3,105,225 — — $ 3,105,225 As of December 31, 2017 Description Total Level 1 Level 2 Level 3 Liabilities: Contingent consideration $ 2,609,289 — — $ 2,609,289
Schedule of Level 3 Fair Value Measurements	The following table summarizes the change in fair value, as determined by Level 3 inputs, for all assets and liabilities using unobservable Level 3 inputs for the year ended December 31, 2018: Contingent Consideration Balance at December 31, 2016 $ — Acquisition of Pelican 2,385,000 Change in fair value 224,289 Balance at December 31, 2017 2,609,289 Change in fair value 495,936 Balance at December 31, 2018 $ 3,105,225
Schedule of Fair Value Measurements of Contingent Consideration	The following table presents quantitative information about the inputs and valuation methodologies used for the Company’s fair value measurements of contingent consideration classified as Level 3 as of December 31, 2018: Valuation Significant Weighted Average Contingent Consideration Probability weighted Milestone dates 2019-2025 Discount rate 13.82% to 3.66% Probability of occurrence 23% to 86%

Short-Term Investments (Tables)

Short-Term Investments (Tables)	12 Months Ended
	Dec. 31, 2018
Short-term Investments [Abstract]
Schedule of Short-Term Investments	The following summarizes information about short term investments at December 31, 2018 and 2017, respectively: Amortized Gross Estimated 2017 Certificates of deposit, commercial paper $ — $ — $ — 2018 Certificates of deposit, commercial paper $ 5,570,158 $ (131 ) $ 5,570,027

Acquisition of Pelican Therap_2

Acquisition of Pelican Therapeutics (Tables)	12 Months Ended
	Dec. 31, 2018
Business Combinations [Abstract]
Schedule of Assets Acquired and Liabilities Assumed in Acquisition	The purchase price has been allocated to the assets and liabilities as follows: Aggregate consideration: Cash consideration $ 500,000 Stock consideration $ 1,052,000 Contingent consideration $ 2,385,000 Total Consideration $ 3,937,000 Purchase price allocation: Cash acquired $ 31,199 In-process R&D $ 5,866,000 Goodwill $ 2,189,338 Deferred tax liability $ (2,111,760 ) Net liabilities assumed $ (1,102,777 ) Fair value of non-controlling interest $ (935,000 ) Total purchase price $ 3,937,000
Schedule of Pro Forma Financial Information for Acquisition	The following unaudited pro forma information presents the combined results of operations for the year ended December 31, 2017, as if we had completed the Pelican acquisition at the beginning of fiscal 2017. The pro forma financial information is provided for comparative purposes only for the year ended December 31, 2017 and is not necessarily indicative of what actual results would have been had the acquisition occurred on the date indicated, nor does it give effect to synergies, cost savings, fair market value adjustments, immaterial amortization expense and other changes expected to result from the acquisition. Accordingly, the pro forma financial results do not purport to be indicative of consolidated results of operations as of the date hereof, for any period ended on the date hereof, or for any other future date or period. (in millions except per share value) December 31, 2017 (unaudited) Grant and licensing revenue $ 1.5 Net loss (12.8 ) Net loss: Non-controlling interest (0.6 ) Net loss attributable to Heat Biologics, Inc. $ (12.2 ) Net loss per share attributable to Heat Biologics, Inc.—basic and diluted $ (3.16 )

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Prepaid Expenses And Other Current Assets Tables Abstract
Schedule of Prepaid Expenses and Other Current Assets	5. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following at: December 31, 2018 2017 Prepaid manufacturing expense $ 559,110 $ 1,551,597 Prepaid insurance 284,931 218,750 Other prepaid expenses 117,261 87,937 Other current assets 15 108,973 $ 961,317 $ 1,967,257

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following at: December 31, 2018 2017 Lab equipment $ 1,218,532 $ 645,433 Leasehold improvements 9,445 — Computers 38,589 41,333 Furniture and fixtures 58,146 55,883 Total 1,324,712 742,649 Accumulated depreciation (681,566 ) (455,758 ) Property and equipment, net $ 643,146 $ 286,891

Goodwill and In-process R&D (Ta

Goodwill and In-process R&D (Tables)	12 Months Ended
	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill and In-process R&D	The following table provides a rollforward of the Company’s goodwill as of December 31, 2017 and 2018: Goodwill Goodwill from acquisition of Pelican $ 2,189,338 Balance at December 31, 2017 2,189,338 Purchase accounting adjustments — Balance at December 31, 2018 $ 2,189,338 The following table provides a rollforward of the Company’s in-process R&D as of December 31, 2017 and 2018: In-process R&D In-process R&D from acquisition of Pelican $ 5,866,000 Balance at December 31, 2017 5,866,000 Purchase accounting adjustments — Balance at December 31, 2018 $ 5,866,000

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2018
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Expenses and other payables	Accrued expenses consist of the following at: December 31, 2018 2017 Accrued clinical trial expenses $ 919,750 $ 1,504,240 Compensation and related benefits 628,147 542,434 Patent fees 40,000 40,000 Deferred rent 7,854 27,457 Other expenses 82,300 162,300 $ 1,678,051 $ 2,276,431

License Agreements (Tables)

License Agreements (Tables)	12 Months Ended
	Dec. 31, 2018
License Agreements Tables
Schedule of Future Minimum Royalty Payments	Future minimum royalty payments by the Company for licenses as of December 31, 2018 are as follows (in thousands): Year ended December 31, 2019 $ 74 2020 103 2021 228 2022 784 2023 74 Total $ 1,263

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Common Stock Warrants by Exercise Price Range	The Company has a total of 9,030,730 warrants outstanding at a weighted average exercise price of $1.89 to purchase its common stock as of December 31, 2018. These warrants are summarized as follows: Issuance Date Number of Shares Exercise Price Expiration Date 3/10/2011 1,738 $ 4.80 3/10/2021 3/23/2016 296,159 $ 10.00 3/23/2021 5/7/2018 4,132,833 $ 1.58 5/8/2023 11/26/2018 4,600,000 $ 1.65 11/26/2023
Common Stock Warrants Outstanding	The following table summarizes the warrant activity of the Company’s common stock warrants: Common Stock Warrants Outstanding, December 31, 2016 310,397 Exercised — Expired — Outstanding, December 31, 2017 310,397 Issued 11,787,500 Exercised 3,054,667 Expired (12,500 ) Outstanding, December 31, 2018 9,030,730
Schedule of Components of Stock-based Compensation Included in Net Loss	The following table summarizes the components of the Company’s stock-based compensation included in net loss: For the years ended December 31, 2018 2017 Employee stock options $ 443,684 $ 474,251 Non-employee stock options 20,420 14,362 Employee stock awards 318,186 169,517 Non-employee stock awards 6,369 31,000 $ 788,659 $ 689,130
Schedule of Stock Option Valuation Assumptions	The fair value of each stock option is estimated on the date of grant using the Black-Scholes-Merton option pricing model with the following assumptions for stock options granted during the years ended: December 31, 2018 2017 Dividend yield 0.0 % 0.0 % Expected volatility 83.63-121.81 % 76.35-79.08 % Risk-free interest rate 2.32-2.98 % 1.86-2.26 % Expected term (years) 5.1-6.3 5.8-7.8
Schedule of Stock Option Activity	The following tables summarize the stock option activity for the year ended December 31, 2018: Shares Weighted Average Exercise Price Outstanding, December 31, 2017 266,810 $ 19.57 Granted 221,410 $ 3.57 Exercised — $ — Forfeited/Expired (22,917 ) $ 26.97 Outstanding, December 31, 2018 465,303 $ 11.60
Schedule of Options Outstanding, Vested and Exercisable	The following table summarizes information about stock options outstanding at December 31, 2018: Options Outstanding Options Vested and Exercisable Balance as of 12/31/2018 Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Balance as of 12/31/2018 Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price 465,303 8.17 $11.60 198,957 7.21 $20.48

Income Tax (Tables)

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Tables
Schedule of Components of Income Tax Expense	The components of income tax expense (benefit) attributable to continuing operations are as follows: 2018 2017 Current Expense: Federal $ — $ — State — — Foreign — — — — Deferred Expense: Federal $ (985,488 ) $ (762,580 ) State — (46,960 ) Foreign — — Total $ (985,488 ) $ (809,540 )
Schedule of Income Tax Rate Reconciliation	The differences between the company’s income tax expense attributable to continuing operations and the expense computed at the 21 % United States statutory income tax rate were as follows: 2018 2017 Federal income tax expense at statutory rate: $ (3,577,000 ) $ (4,495,000 ) Increase (reduction) in income tax resulting from: State Income Taxes (207,000 ) (194,000 ) Foreign Rate Differential (17,000 ) (16,000 ) Nondeductible Expenses 7,000 9,000 Prior Period True-Up - Pelican 208,000 — Research & Development Credit (763,000 ) (409,000 ) Stock Based Compensation 60,000 84,000 Acquisition Costs — 96,000 Reserve for Loss Carryforwards Limited by Sec. 382 22,000 (541,000 ) Tax Reform Impact — (8,024,000 ) Other 25,512 45,460 Increase (Decrease) in Valuation Allowance 3,256,000 (3,445,000 ) $ (985,488 ) $ (809,540 )
Schedule of Deferred Tax Assets and Liabilities	The tax effects of temporary differences and operating loss carryforwards that gave rise to significant portions of the deferred tax assets and deferred tax liabilities were as follows at December 31, 2018 and December 31, 2017: 2018 2017 Deferred tax assets: Net Operating Loss Carryfowards $ 18,731,555 $ 15,117,487 R&D Credits 2,729,737 1,966,964 Stock Compensation 744,506 629,447 Contingent Consideration 713,259 599,343 Other Accrued Expenses — 128,522 Deferred tax assets 22,919,057 18,441,763 Deferred tax liabilities: Property, plant and equipment, primarily due to differences in depreciation (127,140 ) (26,307 ) Other Accrued Expenses (11,926 ) — Intangible Assets (1,302,220 ) (1,302,220 ) Deferred tax liabilities (1,441,286 ) (1,328,527 ) Valuation allowance (21,794,504 ) (18,415,456 ) Net deferred tax assets (liabilities) $ (316,733 ) $ (1,302,220 )

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share	The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.: For the years ended December 31, 2018 2017 Net loss $ (16,591,293 ) $ (12,409,866 ) Net loss - Non-controlling interest (857,439 ) (568,195 ) Net loss attributable to Heat Biologics, Inc. $ (15,733,854 ) $ (11,841,671 ) Weighted-average number of common shares used in net loss per share attributable to common stockholders —basic and diluted 17,485,461 3,845,342 Net loss per share attributable to Heat Biologics, Inc —basic and diluted $ (0.90 ) $ (3.08 )
Schedule of Potentially Dilutive Securities	The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect: For the years ended December 31, 2018 2017 Outstanding stock options 465,303 266,810 Unvested restricted stock units 56,520 21,779 Outstanding common stock warrants 9,030,730 310,397

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	The Company’s approximate future minimum payments for its operating lease obligations that have initial remaining non-cancelable terms in excess of one year are as follows: Years ending December 31, 2019 309,729 2020 115,580 2021 118,158 2022 120,736 2023 20,194 Total $ 684,397

Organization (Details)

Organization (Details)	Dec. 31, 2018	Dec. 31, 2017
Pelican Therapeutics, Inc. [Member]
Noncontrolling Interest [Line Items]
Percentage of voting interests acquired in acquisition	85.00%	80.00%
Heat Biologics I, Inc [Member]
Noncontrolling Interest [Line Items]
Ownership interest in subsidiary	100.00%	92.50%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)	1 Months Ended			12 Months Ended
	May 31, 2018	Oct. 31, 2017	May 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Nov. 02, 2017	Dec. 31, 2016
Revenue				$ 5,793,849	$ 1,519,943
Accumulated deficit				84,580,180	68,846,326
Net loss				16,591,293	$ 12,409,866
Cash, cash equivalents and short term investments				$ 27,700,000
Shares issued in acquisition					133,106
Restricted cash				$ 0	$ 2,292
Restricted cash from cash flows				22,154,251	9,765,359		$ 7,943,838
Cash balance insured				250,000	250,000
Cash balance uninsured				21,904,251
Fair value of the contingent consideration				$ 495,936	$ 224,289
Federal corporate tax rate				21.00%
Unearned revenue liability balance				$ 1,000,000
Lab equipment [Member]
Useful life				P5Y
Computers [Member]
Useful life				P5Y
Furniture and Fixtures [Member]
Useful life				P7Y
Heat Biologics I, Inc [Member]
Ownership interest in subsidiary				100.00%	92.50%
CPRIT [Member]
Deferred revenue				$ 1,000,000
Grant received						$ 200,000
Heat I, Inc. and Pelican [Member]
Shares issued in acquisition				35,000
Pelican Therapeutics, Inc. [Member]
Revenue				$ 150,000
Net loss				$ 170,000
Percentage of voting interests acquired in acquisition				85.00%	80.00%
Shares issued in acquisition				133,106
Amount awarded from CPRIT grant	$ 15,200,000			$ 7,600,000
Contract value				$ 7,300,000
Pelican Therapeutics, Inc. [Member] | Second tranche [Member] | Grant Revenue [Member]
Revenue		$ 6,500,000
Pelican Therapeutics, Inc. [Member] | First tranche [Member] | Grant Revenue [Member]
Revenue			$ 1,800,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Schedule of Fair Value of Financial Instruments Measurements) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Assets:
Short-term investments	$ 5,570,027
Liabilities:
Contingent consideration	1,918,225	2,609,289
Level 1 [Member]
Assets:
Short-term investments	5,750,027
Liabilities:
Contingent consideration
Level 2 [Member]
Assets:
Short-term investments
Liabilities:
Contingent consideration
Level 3 [Member]
Assets:
Short-term investments
Liabilities:
Contingent consideration	$ 3,105,225	$ 2,609,289

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Schedule of Fair Value Measurements) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Beginning Balance	$ 2,609,289
Acquisition of Pelican		2,385,000
Change in fair value	495,936	224,289
Ending Balance	$ 3,105,225	$ 2,609,289

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Schedule of Fair Value Measurements of Contingent Consideration) (Details)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Valuation Methodology	Probability weighted income approach
Significant unobservable input - milestone dates	2019-2025
Discount rate - minimum	3.66%
Discount rate - maximum	13.82%
Probability of occurrence - minimum	23.00%
Probability of occurrence - maximum	86.00%

Short-Term Investments (Schedul

Short-Term Investments (Schedule of Short Term Investments) (Details) - Certificates of deposit, commercial paper [Member] - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Estimated fair value	$ 5,570,027
Gross unrealized losses	(131)
Amortized cost	$ 5,570,158

Acquisition of Pelican Therap_3

Acquisition of Pelican Therapeutics (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	May 31, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Issuance of common stock Pelican, shares			133,106
Accrued liabilities		$ 1,678,051	$ 2,276,431
Goodwill		2,189,338	2,189,338
In-process R&D		5,866,000	5,866,000
Revenue		5,793,849	1,519,943
Net loss (income)		$ (15,733,854)	$ (11,841,671)
Pelican Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Percentage of voting interests acquired in acquisition		85.00%	80.00%
Issuance of common stock Pelican, shares		133,106
Percentage of outstanding common shares issued for equity consideration in business acquisition		4.99%
Percentage of probability-weighted		7.20%
Cash consideration		$ 500,000
Accrued liabilities		200,000
Fair value of contingent consideration		500,000	$ 200,000
Goodwill		2,189,338
In-process R&D		$ 5,900,000
Percentage of non-controlling interest acquired		20.00%
Revenue		$ 150,000
Amount awarded from CPRIT grant	$ 15,200,000	7,600,000
Total matching funds provided by Company		5,200,000
Remaing matching funds to be provided by Company		3,500,000
Remaining matching funds to be provided by Company for third fiscal year		7,600,000
Total grant funds provided by CPRIT		8,300,000
Remaining grant funds to be provided by CPRIT		$ 6,900,000
Pelican Therapeutics, Inc. [Member] | Minimum [Member]
Business Acquisition [Line Items]
Percentage of non-controlling interest acquired		10.00%
Pelican Therapeutics, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Percentage of non-controlling interest acquired		15.00%
Pelican Therapeutics, Inc. [Member] | Stockholders [Member]
Business Acquisition [Line Items]
Cash consideration		$ 300,000

Acquisition of Pelican Therap_4

Acquisition of Pelican Therapeutics (Future Milestone Payments) (Details) - Pelican Therapeutics, Inc. [Member]	Dec. 31, 2018USD ($)
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 1 trial for an oncology indication	$ 2,000,000
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 2 trial for an oncology indication	1,500,000
Future milestone payment upon successful outcome of the first Phase 2 trial for an oncology indication	3,000,000
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 3 trial for an oncology indication	6,000,000
Future milestone payment upon Pelican's dosing of the first patient in its first Phase 3 trial for a non- oncology indication	3,000,000
Future milestone payment upon successful outcome of the first Phase 3 trial for an oncology indication	7,500,000
Future milestone payment upon successful outcome of the first Phase 3 trial for a non-oncology indication	3,000,000
Future milestone payment upon acceptance of a Biologics License Application (BLA) submission for an oncology indication	7,500,000
Future milestone payment upon acceptance of a BLA submission for a non-oncology indication	3,000,000
Future milestone payment upon first product indication approval in the United States or Europe for an oncology indication	7,500,000
Future milestone payment upon first product indication approval in the United States or Europe for a non- oncology indication	$ 3,000,000
Discount rate used for calculation of fair value of contingent consideration	7.20%

Acquisition of Pelican Therap_5

Acquisition of Pelican Therapeutics (Schedule of Purchase Price of Assets and Liabilities) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Aggregate consideration:
Contingent consideration		$ 2,385,000
Purchase price allocation:
Goodwill	2,189,338	$ 2,189,338
Pelican Therapeutics, Inc. [Member]
Aggregate consideration:
Cash consideration	500,000
Stock consideration	1,052,000
Contingent consideration	2,385,000
Total Consideration	3,937,000
Purchase price allocation:
Cash acquired	31,199
In-process R&D	5,866,000
Goodwill	2,189,338
Deferred tax liability	(2,111,760)
Net liabilities assumed	(1,102,777)
Fair value of non-controlling interest	(935,000)
Total purchase price	$ 3,937,000

Acquisition of Pelican Therap_6

Acquisition of Pelican Therapeutics (Schedule of Pro Forma Financial Information for Acquisition) (Details) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2017USD ($)$ / shares
Business Combinations [Abstract]
Grant and licensing revenue	$ 1.5
Net loss	(12.8)
Net loss: Non-controlling interest	(0.6)
Net loss attributable to Heat Biologics, Inc.	$ (12.2)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted | $ / shares	$ (3.16)

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Schedule of Prepaid Expenses and Other Current Assets) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Prepaid Expenses And Other Current Assets Schedule Of Prepaid Expenses And Other Current Assets
Prepaid manufacturing expense	$ 559,110	$ 1,551,597
Prepaid insurance	284,931	218,750
Other prepaid expenses	117,261	87,937
Other current assets	15	108,973
Prepaid expenses and other current assets	$ 961,317	$ 1,967,257

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Total	$ 1,324,712	$ 742,649
Accumulated depreciation	(681,566)	(455,758)
Property and equipment, net	643,146	286,891
Depreciation expense	$ 237,318	134,084
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 1,218,532	645,433
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	9,445
Computers [Member]
Property, Plant and Equipment [Line Items]
Total	38,589	41,333
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	$ 58,146	$ 55,883

Goodwill and In-process R&D (Sc

Goodwill and In-process R&D (Schedule of Goodwill) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill beginning balance	$ 2,189,338
Goodwill from acquisition of Pelican		2,189,338
Purchase accounting adjustments
Goodwill ending balance	$ 2,189,338	$ 2,189,338

Goodwill and In-process R&D (_2

Goodwill and In-process R&D (Schedule of In-process R&D) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
In-process R&D beginning balance	$ 5,866,000
In-process R&D from acquisition of Pelican	5,866,000	5,866,000
Purchase accounting adjustments
In-process R&D ending balance	$ 5,866,000	$ 5,866,000

Accrued Expenses (Schedule of A

Accrued Expenses (Schedule of Accrued Expenses) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accrued Liabilities, Current [Abstract]
Accrued clinical trial expenses	$ 919,750	$ 1,504,240
Compensation and related benefits	628,147	542,434
Patent fees	40,000	40,000
Deferred rent	7,854	27,457
Other expenses	82,300	162,300
Accrued expenses	$ 1,678,051	$ 2,276,431

License Agreements (Narrative)

License Agreements (Narrative) (Details) - USD ($)	1 Months Ended								12 Months Ended
	Oct. 25, 2016	Jun. 30, 2016	Nov. 19, 2013	Jul. 31, 2011	Apr. 30, 2011	Feb. 28, 2011	Jun. 30, 2009	Apr. 30, 2009	Dec. 31, 2018	Dec. 31, 2010	Dec. 31, 2017	May 30, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Sep. 08, 2010
Additional consideration								$ 12,500
Minimum royalty payment for first three years, per year										$ 10,000							$ 10,000	$ 10,000
Minimum royalty payment for remainer life of agreement, per year									$ 20,000		$ 20,000		$ 20,000	$ 20,000	$ 20,000	$ 20,000
Milestone payment											1,000	$ 500,000
Milestone payment upon annual net sales of $100,000,000 or more													250,000
Option fees																			$ 2,000
Exercise of stock options				$ 10,000
Maintenance fee	$ 82,000
Upfront fee	$ 20,000
Pelican Therapeutics, Inc. [Member]
Minimum royalty payment for first three years, per year										10,000							10,000	$ 10,000
Minimum royalty payment for remainer life of agreement, per year									20,000		20,000		20,000	20,000	20,000	20,000
License agreement ("SS114A") [Member]
Reimbursement of for past patent fees						$ 37,381
License Agreement ("143") [Member]
Reimbursement of for past patent fees						50,000
License Agreement ("J110") [Member]
Reimbursement of for past patent fees						10,000
License Agreement for Multiple Myeloma [Member]
Maintenance fee									5,000
License 0331, 0539 [Member] | Pelican Therapeutics, Inc. [Member]
Milestone payments due upon submission									150,000
Milestone payments completion of phase 1 clinical trial									250,000
License I176 [Member] | Pelican Therapeutics, Inc. [Member]
Minimum royalty payment for first three years, per year															$ 10,000	$ 10,000	$ 10,000
Minimum royalty payment for remainer life of agreement, per year									20,000		$ 20,000		$ 20,000	$ 20,000
License Costs										50,000
Reimbursement of for past patent fees										$ 15,797
Milestone payments due upon submission									150,000
Milestone payments completion of phase 1 clinical trial									$ 500,000
UMM143 [Member] | Pelican Therapeutics, Inc. [Member]
License Costs			$ 35,000
Not For Profit Corporation Fee Two [Member]
License Costs					$ 50,000
Patents [Member] | License Agreement ("143") [Member]
License Costs						14,158
Patents [Member] | License Agreement ("J110") [Member]
License Costs						$ 1,055
SubsidiaryOneMember | Not For Profit Corporation Fee Two [Member]
Percentage of issued and outstanding stock owned							7.50%
Shattuck Labs, Inc. ("Shattuck") Member
License Costs		$ 50,000

License Agreements (Schedule of

License Agreements (Schedule of Future Minimum Royalty Payments) (Details) $ in Thousands	Dec. 31, 2018USD ($)
License Agreements [Abstract]
2019	$ 74
2020	103
2021	228
2022	784
2023	74
Total	$ 1,263

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($)	Nov. 26, 2018	May 07, 2018	Mar. 15, 2018	Jan. 18, 2018	Aug. 15, 2016	Jan. 31, 2018	Nov. 30, 2017	Mar. 28, 2017	Jan. 31, 2017	Dec. 30, 2016	Dec. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Jul. 22, 2018	Mar. 23, 2016	Feb. 28, 2014	Mar. 10, 2011
Class of Stock [Line Items]
Preferred Stock, par value per share												$ 0.0001	$ 0.0001
Preferred stock, shares authorized												10,000,000	10,000,000
Preferred stock, shares issued												0	0
Preferred stock, shares outstanding												0	0
Issuance of preferred stock, shares												14,375,000	575,000
Common stock, par value per share												$ 0.0002	$ 0.0002
Common stock, shares authorized												100,000,000	100,000,000
Common stock, shares issued												32,492,144	4,200,310
Common stock, shares outstanding												32,492,144	4,200,310
Stock based compensation												$ 788,659	$ 689,130
Restricted stock granted												221,410
Proceeds from sale of common stock												$ 3,910,093	2,463,180
Exercise price of warrants		$ 1.584
Warrants, expiry period		5 years
Proceeds from exercise of warrants												$ 4,838,593
Reverse stock split												1-for-10
Reduce number of issued and outstanding common stock												4,200,000	4,200,000
Exercise of warrants, shares												3,054,667
Common warrant [Member]
Class of Stock [Line Items]
Public offering price		$ 0.01
Pre-funded warrant [Member]
Class of Stock [Line Items]
Public offering price		1.43
Restricted Stock [Member] | Employees [Member]
Class of Stock [Line Items]
Stock based compensation												$ 318,186	$ 169,517
Restricted stock granted						60,375			35,989
Vested restricted stock						15,092
Vesting period						3 years			1 year
Restricted Stock [Member] | Employees [Member]
Class of Stock [Line Items]
Restricted stock granted									42,850
Vested restricted stock									10,713
Vesting period									3 years
Restricted Stock [Member] | Non Employees [Member]
Class of Stock [Line Items]
Stock based compensation						$ 6,369
Restricted stock granted						3,250
Vested restricted stock						812
Vesting period						3 years
Restricted Stock [Member] | Vesting immediately [Member]
Class of Stock [Line Items]
Vesting percentage										25.00%
Common Stock Warrant [Member]
Class of Stock [Line Items]
Price per share		$ 1.30										$ 1.42					$ 10
Common stock, shares issued															910,000
Warrants to purchase common stock	4,600,000	9,500,000										4,600,000		12,500	682,500	1,523
Exercise price of warrants															$ 0.75
Public offering price		$ 1.44
Underwriting Agreement [Member]
Class of Stock [Line Items]
Proceeds from initial public offering												$ 4,800,000
Price per share												$ 8
Proceeds from sale of common stock			$ 1,300,000	$ 3,700,000								$ 4,100,000
Number of shares sold	1,200,000											75,000
Warrants to purchase common stock	600,000
Exercise of warrants, shares												3,054,667
Underwriting Agreement [Member]
Class of Stock [Line Items]
Shares issued for initial public offering		4,875,000
Proceeds from initial public offering		$ 18,800,000
Price per share	$ 1.50											$ 4.30
Proceeds from sale of common stock	$ 12,700,000											$ 2,400,000
Number of shares sold	8,000,000						581,395	500,000				39,255
Warrants to purchase common stock	4,000,000
Exercise price of warrants	$ 1.65
Underwriting Agreement [Member] | Common warrant [Member]
Class of Stock [Line Items]
Warrants to purchase common stock		2,437,500
Underwriting Agreement [Member] | Pre-funded warrant [Member]
Class of Stock [Line Items]
Warrants to purchase common stock		4,750,000
Sales Agreement [Member]
Class of Stock [Line Items]
Proceeds from sale of common stock											$ 2,300,000	$ 3,800,000
Number of shares sold											234,858	1,566,997
Commission rate percentage					3.00%
Non Employees [Member] | Restricted Stock [Member]
Class of Stock [Line Items]
Stock based compensation												$ 0	$ 31,000

Stockholders' Equity (Common St

Stockholders' Equity (Common Stock Warrants) (Details) - USD ($)	Nov. 26, 2018	May 07, 2018	Mar. 10, 2011	Jul. 22, 2018	Mar. 23, 2016	Feb. 28, 2014	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued							32,492,144	4,200,310
Exercise price of warrant liabilities		$ 1.584
Fair value of common stock							$ 6,499	$ 840
Dividend yield							0.00%	0.00%
Common Stock Warrants
Weighted average price							$ 11.60	$ 19.57
Common Stock Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant outstanding			1,738				0
Warrants exercised							3,054,667
Common stock shares issued					910,000
Number of shares of common stock issuable through warrants	4,600,000	9,500,000		12,500	682,500	1,523	4,600,000
Common stock issued for conversion of warrants		7,187,500
Exercise price of warrant liabilities					$ 0.75
Expiration term	5 years	5 years	10 years	5 years	5 years		5 years		10 years
Exercise price	$ 1.65	$ 1.584	$ 4.80	$ 125	$ 10		$ 1.65		$ 4.80
Price per share		$ 1.30	$ 10				$ 1.42
Fair value of common stock		$ 7,800,000			$ 2,522,754		$ 5,600,000
Dividend yield		0.00%					0.00%
Expected volatility		124.14%					133.26%
Risk-free interest rate		2.78%					2.89%
Expected term (years)		5 years					5 years
Common Stock Warrants
Outstanding, beginning balance								310,397
Granted									3,261
Exercised
Expired
Outstanding, ending balance							9,030,730
Weighted average price							$ 1.89
Number of shares issued from cashless exercise of warrant						1,432
Number of shares outstanding from cashless exercise of warrant						1,738
Pre-funded warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price							$ 0.01
Common Stock Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares issued							296,159
Number of shares of common stock issuable through warrants							4,132,833
Exercise price							$ 1.584
Price per share							$ 10

Stockholders' Equity (Equity Co

Stockholders' Equity (Equity Compensation Plan) (Narrative) (Details) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2009	Dec. 31, 2015	Apr. 30, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding stock options		465,303	266,810
Granted		221,410
Stock-based compensation expense		$ 788,659	$ 689,130
Stock option expense		$ 464,104	$ 488,613
Weighted average grant-date fair value		$ 2.65	$ 5.33
Unrecognized stock-based compensation expense		$ 2,300,000
Unrecognized stock-based compensation expense, recognition period		11 months
Dividend yield		0.00%	0.00%
2009 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Incentive Plan, shares authorized					21,739		65,217
Expiration term					10 years
Outstanding stock options		23,799	24,042
Common shares available for issuance							86,957
2014 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Incentive Plan, shares authorized	50,000
Stock Incentive Plan, shares authorized increased						60,000
Expiration term	10 years
Outstanding stock options		263,484	232,768
Granted	1,100,000
2009 and 2014 Plans [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted				300,000
2017 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Incentive Plan, shares authorized			500,000
Outstanding stock options		234,540	10,000
2018 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Incentive Plan, shares authorized		4,000,000
Outstanding stock options
Common shares available for issuance		4,260,215

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule of Warrants By Exercise Price) (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Number of Shares	465,303	266,810
Exercise Price	$ 11.60	$ 19.57
3/10/2011 [Member]
Issuance Date	Mar. 10, 2011
Number of Shares	1,738
Exercise Price	$ 4.80
Expiration Date	Mar. 10, 2021
3/23/2016 [Member]
Issuance Date	Mar. 23, 2016
Number of Shares	296,159
Exercise Price	$ 10
Expiration Date	Mar. 23, 2021
5/7/2018 [Member]
Issuance Date	May 7, 2018
Number of Shares	4,132,833
Exercise Price	$ 1.58
Expiration Date	May 8, 2023
11/26/2018 [Member]
Issuance Date	Nov. 26, 2018
Number of Shares	4,600,000
Exercise Price	$ 1.65
Expiration Date	Nov. 26, 2023

Stockholders' Equity (Schedul_2

Stockholders' Equity (Schedule of Warrant Activity) (Details) - Warrant [Member] - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning balance	310,397	310,397
Issued	11,787,500
Exercised	3,054,667
Expired	(12,500)
Outstanding, ending balance	9,030,730	310,397

Stockholders' Equity (Schedul_3

Stockholders' Equity (Schedule of Stock-based Compensation) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$ 788,659	$ 689,130
Employee stock options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	443,684	474,251
Employee stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	318,186	169,517
Non-employee stock awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	6,369	31,000
Non Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock based compensation	$ 20,420	$ 14,362

Stockholders' Equity (Schedul_4

Stockholders' Equity (Schedule of Stock Option Valuation Assumptions) (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	83.63%	76.35%
Risk-free interest rate	2.32%	1.86%
Expected term (years)	5 years 1 month 6 days	5 years 9 months 18 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	121.81%	79.08%
Risk-free interest rate	2.98%	2.26%
Expected term (years)	6 years 3 months 19 days	7 years 9 months 18 days

Stockholders' Equity (Schedul_5

Stockholders' Equity (Schedule of Stock Option Activity) (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Shares
Outstanding, beginning balance | shares	266,810
Granted | shares	221,410
Exercised | shares
Forfeited/Expired | shares	(22,917)
Outstanding, ending balance | shares	465,303
Weighted Average Exercise Price
Outstanding, beginning balance | $ / shares	$ 19.57
Granted | $ / shares	3.57
Exercised | $ / shares
Forfeited/Expired | $ / shares	26.97
Outstanding, ending balance | $ / shares	$ 11.60

Stockholders' Equity (Summary o

Stockholders' Equity (Summary of Outstandng Stock Options) (Details)	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Options Outstanding
Balance | shares	465,303
Weighted Average Remaining Contractual Life (Years)	8 years 2 months 1 day
Weighted Average Exercise Price Options Outstanding | $ / shares	$ 11.60
Options Vested or Expected to Vest
Balance | shares	198,957
Weighted Average Remaining Contractual Life (Years)	7 years 2 months 16 days
Weighted average exercise price Options Vested or Expected to Vest | $ / shares	$ 20.48

Income Tax (Narrative) (Details

Income Tax (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Statutory federal tax rate	21.00%
Valuation allowance	$ 21,794,504	$ 18,415,456
Deferred tax liability	985,487	$ 809,540
State Net Operating Loss Carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 73,861,907
Net operating loss carryforwards expiration dates	Dec. 31, 2024
Federal Net Operating Loss Carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 84,517,142
Net operating loss carryforwards expiration dates	Dec. 31, 2029
Pelican Therapeutics [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 3,027,284
State Net Pelican Therapeutics [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	2,922,000
Foreign Net Operating Loss Carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	122,605
Pelican Net Operating Loss Carryforwards [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 2,344,952

Income Tax (Schedule of Income

Income Tax (Schedule of Income Tax Expense (Benefit)) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Current Expense:
Federal
State
Foreign
Current expense
Deferred Expense:
Federal	(985,488)	(762,580)
State		(46,960)
Foreign
Total	$ (985,488)	$ (809,540)

Income Tax (Schedule of Incom_2

Income Tax (Schedule of Income Tax Rate Differences) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal income tax expense at statutory rate:	$ (3,577,000)	$ (4,495,000)
Increase (reduction) in income tax resulting from:
State Income Taxes	(207,000)	(194,000)
Foreign Rate Differential	(17,000)	16,000
Nondeductible Expenses	7,000	9,000
Period True-Up - Pelican	208,000
Research & Development Credit	(763,000)	(409,000)
Stock Based compensation	60,000	84,000
Acquisition Costs		96,000
Reserve for Loss Carryforwards Limited by Sec. 382	22,000	(541,000)
Tax Reform Impact		8,024,000
Other	25,512	45,460
Increase (Decrease) in Valuation Allowance	3,256,000	(3,445,000)
Total	$ (985,488)	$ (809,540)

Income Tax (Schedule of Deferre

Income Tax (Schedule of Deferred Tax Assets) (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net Operating Loss Carryfowards	$ 18,731,555	$ 15,117,487
R & D credits	2,729,737	1,966,964
Stock Compensation	744,506	629,447
Contingent Consideration	713,259	599,343
Other Accrued Expenses		128,522
Deferred tax assets	22,919,057	18,441,763
Deferred tax liabilities:
Property, plant and equipment, primarily due to differences in depreciation	(127,140)	(26,307)
Other Accrued Expenses	(11,926)
Intangible Assets	(1,302,220)	(1,302,220)
Deferred tax liabilities	(1,441,286)	(1,328,527)
Valuation allowance	(21,794,504)	(18,415,456)
Net deferred tax assets (liabilities)	$ (316,733)	$ (1,302,220)

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Pelican, Inc. [Member]
Related Party Transaction [Line Items]
Purchase of ownership interest	5.00%	80.00%
Minimum [Member] | Board One [Member]
Related Party Transaction [Line Items]
Officers' Compensation	$ 61,500	$ 77,000
Maximum [Member] | Board One [Member]
Related Party Transaction [Line Items]
Officers' Compensation	$ 221,000	$ 242,000

Non-Controlling Interest (Detai

Non-Controlling Interest (Details)	Dec. 31, 2018	Dec. 31, 2017
Pelican Therapeutics, Inc. [Member]
Noncontrolling Interest [Line Items]
Percentage of voting interests acquired in acquisition	85.00%	80.00%
Heat Biologics I, Inc [Member]
Noncontrolling Interest [Line Items]
Ownership interest in subsidiary	100.00%	92.50%

Net Loss Per Share (Schedule of

Net Loss Per Share (Schedule of Reconciliation of Net Loss to Net Loss Attributable to Heat Biologics, Inc.) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Earnings Per Share [Abstract]
Net loss	$ (16,591,293)	$ (12,409,866)
Net loss: Non-controlling interest	(857,439)	(568,195)
Net loss attributable to Heat Biologics, Inc.	$ (15,733,854)	$ (11,841,671)
Weighted-average number of common shares used in net loss per share attributable to common stockholders - basic and diluted	17,485,461	3,845,342
Net loss per share applicable to Heat Biologics, Inc - basic and diluted	$ (0.9)	$ (3.08)

Net Loss Per Share (Schedule _2

Net Loss Per Share (Schedule of Antidilutive Securities) (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Employee stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	465,303	266,810
Unvested restricted stock units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	56,520	21,779
Common Stock Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities	9,030,730	310,397

Commitments and Contingencies_2

Commitments and Contingencies (Narrative) (Details)	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Jan. 02, 2018ft²	Jan. 24, 2014ft²
Commitments and Contingencies Disclosure [Abstract]
Lease term			5 years	5 years
Area of office and laboratory space under lease (in square feet) | ft²			5,156	5,979
Rent expense | $	$ 305,391	$ 226,001

Commitments and Contingencies_3

Commitments and Contingencies (Future Minimum Payments for Operating Lease Obligations) (Details)	Dec. 31, 2018USD ($)
Approximate future minimum payments for its operating lease obligations that have initial remaining non-cancellable terms in excess of one year
2019	$ 309,729
2020	115,580
2021	118,158
2022	120,736
2023	20,194
Total	$ 684,397